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ABSTRACT
N-methyl-D-aspartate receptors (NMDARs) are vital components of the mammalian 
nervous system that intimately contribute to excitatory neurotransmission. Learning, 
memory formation, synaptic plasticity, and many neurodegenerative diseases are linked with 
NMDARs. In order to study these processes, there is need for scientific tools that can be 
used to examine NMDARs.
Cone snail venom is a mixture of neurotoxins with specific targets in the nervous 
system. Conantokins are a family of conotoxin that inhibit NMDARs and can select for 
different NMDAR subtypes. Therefore, understanding mechanisms of conantokin selectivity 
and using selective conantokins as tools to identify NMDAR subtypes in the brain are 
important advancements for neurobiology.
In this dissertation, Chapters 2 and 3 describe structural studies of conantokin Bk-B 
(conBk-B) and of conantokin R/-B (conR/-B). These conantokins exhibited novel NMDAR 
subtype selectivities and were consequently of interest for structural characterization. The 
ultra-short conBk-B was found to adopt helical conformation similar to that observed in 
other conantokins. ConR/-B was found to be a kinked helix that is unique among structurally 
characterized conantokins. Comparison of conantokin structures, paired with mutational 
analysis, highlighted that residues 5, 6, 8, and 10 determine subtype selectivity in 
conantokins.
Chapter 4 describes biochemical studies of NMDAR ligand-binding domain (LBD) 
proteins for the NR1-2b, NR2A, NR2B, and NR2C NMDAR subtypes. Limited proteolysis
assays showed agonist binding, indicating LBD proteins were correctly folded. Additional 
experiments found no strong interactions between LBD proteins and conantokins. The 
results suggest that additional protein domains, heteromeric NMDARs, or neuronal 
membranes may be required for conantokin-NMDAR binding.
In Chapter 5, conantokins are used to define the NMDAR subtypes in neurons from 
mouse cerebellum. Agonist challenge assays revealed diversity in cerebellar neurons, and 
conantokin R/-B was used to show NR2B NMDAR subtypes in cerebellar neurons of young 
mice. In older mice, a population of neurons with non-NR2B NMDARs was discovered. 
This dissertation demonstrates the first use of conantokins to define NMDAR subtypes in 
live neurons, provides a foundation for understanding neuronal diversity in the brain, and 
establishes NMDAR subtype composition in individual neurons of the developing 
cerebellum.
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CHAPTER 1
BACKGROUND AND INTRODUCTION
Cone snails and their venom 
Cone snails of the genus Conus are venomous predators that live throughout oceans 
of the world. There are over 500 species of cone snail, which are classified into three diverse 
groups that prey on fish, snails, or worms. Cone snails capture and paralyze prey by injection 
of venom through a harpoon-like structure called the radula. The venom is a complex 
mixture of peptide-neurotoxins called conotoxins. In prey, molecular interactions between 
conotoxins and proteins of the nervous system disrupt communication between neurons and 
from neurons to muscles. The net result of envenomation by Conus snails is rapid and 
complete paralysis, which allows snails to engulf their prey.
Cone snails can also use their venom defensively, and human envenomation by cone 
snails has been documented multiple times. Stings from cone snails cause severe neurological 
effects that include pain, paralysis, visual impairment, difficulty breathing, and sometimes 
death1. The first documented observation of human envenomation by a cone snail was 
described in 18482, and additional occurrences of human envenomation led to interest in 
understanding cone snail venom. By the middle of the 20th century, cone snail anatomy and 
mechanisms of venom injection were well understood3. However, little was known about the 
molecular components of Conus venom.
Early research into the molecular nature of Conus venom examined effects of venom 
injection on animals and explored experimental treatments of crude venom. In a seminal 
paper from 1960, Kohn, Saunders, and Wiener noted that Conus venom was made of 
proteins, had multiple components, and that venom composition varied across cone snail 
species4. These findings fueled increased interest in Conus venom and by the 1980s several 
neurotoxic peptides that generated unique behaviors in animal assays had been characterized.
Conotoxins from Conus geographus were the first to be purified to homogeneity and 
characterized both structurally and biochemically5,6. The conotoxins were found to act on 
ion channels of the nervous system and some could discriminate between isoforms of highly 
similar ion channels7. Use of conotoxins to study the nervous system garnered much 
attention and a systematic approach to classifying new toxins was adopted8.
Conotoxins
Conotoxins disrupt function of the nervous system via specific interactions with 
numerous transmembrane proteins that participate in neurotransmission. The potency and 
selectivity of conotoxins has fostered development of Conus peptides as scientific tools and 
medicines. Many conotoxins are thoroughly characterized, and the major conotoxin families 
continue to grow as venoms from new Conus species are explored9-11. An overview of select 
conotoxin families, known molecular targets, and proposed mechanisms of action are shown 
in Table 1.1, illustrating the diversity of neurotoxic peptide families found in Conus venoms.
Conotoxin composition varies among cone snail species, and collectively the genus 
Conus is believed to produce over 100,000 unique neuro-active peptides11. This vast pool of 
neurotoxins and the observation that many conotoxins are highly selective for targets in the 
nervous system intimates usefulness to study ion channels of the nervous system and 
suggests that some conotoxins may have medicinal value12.
2
3T ab le 1.1: M ajor conotoxin fam ilies
Conotoxin T arget M echan ism
a-conotoxins Nicotinic acetylcholine receptors Competitive antagonism
^-conotoxins Sodium channels Pore blocker
d-conotoxins Sodium channels Inhibits inactivation
l-conotoxins Sodium channels Enhances inactivation
KM-conotoxins Potassium channels Pore blocker
w-conotoxins Calcium channels Pore blocker
Conantokins N-methyl-D-aspartate receptors Competitive antagonism
Many conotoxins are shown to have therapeutic benefits in mice and some have 
reached human clinical trials for the treatment of neuropathologies ranging from pain to 
epilepsy11,13-17. Of note, the w-conotoxin MVIIA is FDA approved and marketed as 
Ziconotide, Prialt® for the treatment of severe, neuropathic pain18,19. The development of 
w-conotoxin MVIIA into a medicine illustrates that exploration of Conus venoms can lead to 
discovery of novel medications.
In addition to medicinal use, conotoxins are suitable tools for examining the 
molecular, cellular, and functional details of the nervous system. For example, a-conotoxins, 
which specifically inhibit nicotinic acetylcholine receptors (nAChRs), have played a crucial 
role in understanding nAChR form and function20,21. Many a-conotoxins can distinguish 
among different nAChR isoforms and, for this reason, can be used to study cholinergic 
innervation of the nervous system22-25. Some examples of a-conotoxin use include mapping 
of subunit interfaces in nAChRs26, defining composition of nAChRs in live neurons27, and 
examining the physiological role of nAChRs in the mammalian nervous system28-30. 
Additionally, similar progress has been made towards understanding the structure and 
function of voltage gated sodium channels31-33 and voltage gated calcium channels34,35, which 
can be studied using ^-conotoxins and w-conotoxins, respectively.
Similar to the examples above, conantokins are a family of conotoxin with 
tremendous potential for examining molecular and cellular details of the nervous system. 
Conantokins inhibit N-methyl-D-aspartate (NMDA) type glutamate receptors and can have 
selectivity for various receptor isoforms36-38. Therefore, conantokins can be used to study 
NMDA receptor (NMDAR) form and function in the nervous system. NMDARs are 
excitatory ion channels that contribute to various neurological and physiological processes 
such as long-term potentiation, synaptic plasticity, learning, and memory39-42. Additionally, 
evidence suggests that NMDARs are involved in many neurodegenerative diseases that 
involve calcium toxicity42. Hence, in addition to utility for studying NMDARs, conantokins 
could be developed into medicines for future treatment of NMDAR-associated nervous 
system disorders.
NMDARs of the mammalian nervous system 
NMDARs are part of the glutamate receptor superfamily of ligand-gated and G 
protein-coupled transmembrane protein receptors that respond to the neurotransmitter 
glutamate. Glutamate is the most abundant excitatory neurotransmitter in the mammalian 
nervous system, and glutamatergic synapses can contain multiple types of glutamate 
receptors. These include receptors that open an ion channel, the ionotropic glutamate 
receptors, and receptors that initiate intracellular signaling through G proteins, the 
metabotropic glutamate receptors 43. Three families of ionotropic glutamate receptors are 
well characterized; the a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
(AMPARs); the kainate receptors (KARs); and the NMDARs43,44. Although AMPARs, 
KARs, and NMDARs all respond to the agonist glutamate, they exhibit distinctive kinetic 
properties, have different requirements for activation, and are likely to have unique
4
physiological functions45. This dissertation focuses on NMDARs, which are of utmost 
interest due to a central physiological role and an interaction with conantokin peptides from 
Conus venom.
The NMDA type glutamate receptor is a tetrameric, transmembrane protein complex 
that is assembled from at least two gene products. In mammals, many NMDAR subtypes are 
found that differ in subunit composition. Diversity in mammalian NMDARs arises from 
differential assembly of NR1 subunits (with eight splice variants), NR2 subunits (with four 
homologous genes), and NR3 subunits (with 2 homologous genes)44,46-48. The NMDAR 
subunits found in mammals are shown in Figure 1.1, panel A.
Functional NMDAR tetramers have two obligatory NR1 subunits and a combination 
of NR2 and/or NR3 subunits49. The most commonly studied NMDAR is a diheteromeric 
assembly consisting of one NR1 variant and one NR2 variant. Examples of diheteromeric 
NMDARs are shown in Figure 1.1, panel B. However, it is evident that more complex 
triheteromeric assemblies are present in vivo (e.g., NR12/NR2A/NR2B)50-53. Examples of 
triheteromeric NMDARs are shown in Figure 1.1, panel C. Ultimately, there is extreme 
diversity in tetrameric NMDAR subtypes that can be generated from differential assembly of 
NMDAR subunits.
The diversity of possible NMDAR tetramers generates many questions. Which 
subtypes are present in real neurons? What is the physiological role of each subtype? Do 
individual neurons express one, or many subtypes? How are these subtypes distributed in the 
brain? However, technical limitations make identification of exact NMDAR subunit 
combinations difficult. Nonetheless, a variety of NMDAR subtypes have been positively 
identified in mammalian neurons.
5
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Figure 1.1: D iversity of potential NMDAR subtypes. A: Eight splice variants of NR1, 
four homologous NR2 genes, and two homologous NR3 genes encode the NMDA receptor 
subunits in mammals. B: Examples of diheteromeric receptors assembled from NR1-1a and 
the four NR2 gene products. C: Examples of triheteromeric receptors assembled from 
combinations of NR2 and NR3 paired with NR1 splice variants.
Diheteromeric NMDARs are the most intensely studied subtype in heterologous 
systems due to ease of data analysis. In vivo, however, evidence suggests that diheteromeric 
receptors often coexist with triheteromeric receptors, and in some cases triheteromeric 
receptors are most prevalent54-57. For example, NR12/NR2A/NR2B triheteromeric receptors 
are the predominant NMDAR in the hippocampus and other regions of the central nervous 
system51-53. Also, NR12/NR2B/NR2D triheteromers are found in dopaminergic neurons of 
the substantia nigra58. Intriguingly, the triheteromeric receptors have unique functional 
properties compared to diheteromeric receptors, which implicates unique physiological roles 
for each NMDAR subtype59,60. Adding to the complexity, NR3 subunits also co-assemble 
with NR2 or other NR3 subunits, creating yet another set of functionally unique NMDAR
61-63subtypes .
In addition to organizational complexity, NMDARs also have a high degree of 
complexity for receptor activation and regulation at the molecular level. In NR12/NR22 
diheteromeric NMDA receptors, opening of the ion-channel requires the co-agonists 
glutamate and glycine, together with membrane depolarization that removes a magnesium 
ion block of the ion-channel pore64,65. In triheteromeric receptors, such as a 
NR12/NR21/NR31 combination, activation is influenced more strongly by glycine because 
glycine is an agonist of the NR3 subunit61,62. Beyond basic activation requirements, many 
molecules modulate NMDAR function, and these generally interact with the extracellular 
amino-terminal domain (ATD). For example, zinc binds the ATD and is a potent inhibitor 
of most NMDA receptor subtypes66-68, especially those containing NR2A69 and NR2B70 
subunits. Additionally, polyamines such as spermine and spermidine influence NDMAR 
activation through interaction with the ATD71-73. Also, protons can antagonize NMDARs via 
interactions with the ATD74-76. All together, NMDARs are complex assemblies of four
7!
protein subunits that behave in a dynamic and regulated manner, which implies that 
NMDARs have complex functions in neurotransmission.
Recently, major advances have been made in understanding the atomic structures of 
NMDA receptors and determining molecular features that confer functions such as voltage 
sensitivity and regulation of receptor activity. Examples include, a crystal structure of the 
ligand-binding domain (LBD) from NR1 that revealed a clamshell-like mechanism of ligand 
binding77. The crystal structure of a NR1-NR2A LBD heterodimer, which illustrated a partial 
subunit interface78. The structure of the NR2B ATD that showed binding sites for various 
regulatory molecules79. Finally, the ATD NR1-NR2B dimer, which revealed additional 
subunit interfaces and regulator binding sites important for NMDAR modulation. Although 
these and additional structures80-82 have led to many novel discoveries, the most influential 
structure will be that of the recently published NMDAR tetramer, which divulged all subunit 
interfaces and domains of the NMDAR including the ATD, LBD, and transmembrane 
domain (TMD)83. Figure 1.2 depicts this NMDAR tetramer (PDB id: 4PE5) and highlights 
regions that are important for activation, inhibition, and modulation of NMDARs.
NMDARs have critical roles in nervous system development, synaptic plasticity, 
learning, and memory, and are implicated in a variety of disease states such as Alzheimer’s, 
Parkinson’s, multiple sclerosis, and epilepsy42,84-89. The mammalian nervous system contains 
many NMDAR subtypes and little is understood on how each subtype contributes to 
nervous system development, function, and disease39,42,78,85,90,91. In order to study the form 
and function of NMDAR subtypes in the mammalian nervous system, pharmacological tools 
that are selective for the various NMDAR subtypes are necessary. Fortunately, conantokin 
peptides from Conus venoms provide an avenue for that discovery and development of tools 
that can be used to study NMDARs.
8
9Figure 1.2: NMDAR structure. A: Horizontal view o f a NMDAR tetramer containing two 
NR1 (grey) and two NR2B (red) subunits shown as a cartoon. (PDB id: 4PE5). Locations of 
the amino-terminal domain (ATD), ligand-binding domain (LBD) and transmembrane 
domain (TMD) are shown. B: Top-down view of the NMDAR tetramer, ATD in 
foreground, illustrating the central ion-channel pore. C: A single NR2B subunit shows 
domain organization in NMDAR subunits. Biologically relevant modulators and agonists are 
listed next to the domains that they bind. Glutamate (black spheres) is shown bound to the 
LBD.
Conantokin peptides
Conantokins are peptide-toxins found in Conus venom that inhibit NMDAR 
activation. Generally 9-30 residues in length and rich in y-carboxyglutamate (Gla) residues, 
conantokins adopt a helical conformation by coordination of divalent cations via gla 
residues. Conantokin-G (conG) from Conus geographus was the first conantokin to be 
discovered and was found to induce sleep in young mice and hyperactivity in old mice upon 
intracerebral injection92. Searches for additional conantokins led to identification of
conantokin-T (conT) from Conus tu lipa3, and both conG and conT were found to inhibit 
activation of NMDARs in cultured neurons from rat93,94. Conantokin inhibition of 
NMDARs was then illustrated in a more controlled setting by using heterologously 
expressed NMDARs in Xenopus oocytes95. The selectivity of conantokins for different 
NMDAR subtypes was revealed by comparison of conG to AP5, which is a broad-spectrum 
NMDAR NMDA antagonist96.
Among conotoxins, which are generally cysteine rich and disulfide bond stabilized, 
conantokins are unique because they contain few cysteine residues, but many gla residues. 
Because of this, structural analysis has been a priority for conantokin researchers. NMR 
spectroscopy and circular dichroism (CD) studies indicate that conG and conT interact with 
calcium ions, which causes increased peptide helicity97. Furthermore, calcium-stabilized 
helical structures of conG and conT have been determined by NMR spectroscopy98-100. 
These studies and others show that gla residues stabilize a helical conformation by 
coordinating calcium ions, which results in alignment of gla residues on a single helical 
face101-105. Interestingly, calcium-chelating agents have little effect on conantokin inhibition of 
NMDARs106,107. This finding suggests that conantokins do not need helical structure to 
inhibit NMDARs, or that the conantokin-NMDAR interactions independently stabilize 
helical structure.
Two mechanisms have been proposed to describe mechanisms for conantokin 
inhibition of NMDARs. Some evidence indicates that conantokins act competitively near the 
glutamate-binding site on the LBD95. Other observations suggest conantokins interact near 
the spermine-binding site on the ATD108,109. However, neither of these mechanisms has been 
conclusively proven, and it may be the case that conantokins have more complex 
interactions with multiple domains of the NMDAR.
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Conantokins as tools to study NMDARs 
Conantokins that are selective for single NMDAR subtypes can be used as tools to 
examine the NMDARs in the nervous system. This dissertation aims to advance our 
understanding of conantokin peptides and NMDA receptors in three major ways. First, 
novel conantokins with unique subtype selectivities are described, which shows that 
conantokins with new selective properties can be found through exploration of Conus 
venoms. Second, structural studies on conantokin peptides illustrate the molecular 
determinants of selectivity, which will enable discovery and development of increasingly 
selective conantokins. Third, conantokin peptides are used to define NMDAR subtypes in 
live neurons, which proves that conantokins are useful tools for understanding NMDARs of 
the nervous system.
Summary of this dissertation 
This dissertation examines conantokin peptides at many levels. The experiments 
described herein include structural studies that reveal atomic details of conantokins, 
biochemical studies to examine conantokin-NMDAR binding, and calcium imaging studies 
that use conantokins to define NMDAR subtypes in living neurons.
In Chapter 2, the discovery and characterization of novel conantokins from Conus 
bocki are described. These were the first conantokins to show preference for NMDARs 
containing the NR2D subunit. Additionally, conBk-B from bocki was found to be the 
shortest naturally occurring conantokin described to date (9 residues) and the NMR solution 
structure of conBk-B was presented.
Chapter 3 describes the NMR solution structure of conRZ-B, a recently discovered 
and ultra-selective conantokin from Conus rolani. ConRZ-B shows greater than 100-fold
11
selectivity for NMDA receptors containing the NR2B subunit110. The NMR structure of 
conRZ-B showed a distinct kinked-helix conformation that is unique among structurally 
characterized conantokins.
Chapter 4 describes the cloning, expression, purification, and examination of soluble 
NMDAR LBD protein constructs. These proteins were analyzed biochemically for ligand 
binding and conantokin binding. The results show that the LBD proteins bind to cognate 
ligands, but no evidence was found for conantokin binding. In the context of other work, 
the results indicate that NMDAR LBD monomers are not sufficient for conantokin binding.
Chapter 5 illustrates the first use of conantokins to define NMDAR composition in 
live neurons cultured from the cerebellum of mouse. Agonist challenge assays paired with 
calcium imaging revealed the frequency of glutamatergic and cholinergic neurons in mouse 
cerebellar neurons. Additionally, conantokin conRZ-B was used to identify NR2B NMDAR 
subtypes in all cerebellar neurons of young mice, and a population of non-NR2B NMDAR 
subtypes in a subset of neurons from older mice.
As a whole, this work takes the appropriate steps towards understanding 
mechanisms of subtype selectivity in conantokins, shows that conantokins with novel 
properties can be discovered by examining venoms from new Conus species, and illustrates 
the first use of conantokins to define NMDAR subtypes in neurons of the mammalian 
nervous system. These advancements will aid future neurobiologists in understanding the 
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A B S T R A C T
In order to decode the roles that N-methyl-D-aspartate (NMDA) receptors play in excitatory 
neurotransmission, synaptic plasticity, and neuropathologies, there is need for ligands that 
differ in their subtype selectivity. The conantokin family of Conus peptides is the only group 
of peptidic natural products known to target NMDA receptors. Using a search that was 
guided by phylogeny, we identified new conantokins from the marine snail Conus bocki that 
complement the current repertoire of NMDA receptor pharmacology. Channel currents 
measured in Xenopus oocytes demonstrate conantokins conBk-A, conBk-B, and conBk-C 
have highest potencies for NR2D containing receptors, in contrast to previously charac­
terized conantokins that preferentially block NR2B containing NMDA receptors. Con- 
antokins are rich in g-carboxyglutamate, typically 17-34 residues, and adopt helical 
structure in a calcium-dependent manner. As judged by CD spectroscopy, conBk-C adopts 
significant helical structure in a calcium ion-dependent manner, while calcium, on its own, 
appears insufficient to stabilize helical conformations of conBk-A or conBk-B. Molecular 
dynamics simulations help explain the differences in calcium-stabilized structures. Two­
dimensional NMR spectroscopy shows that the 9-residue conBk-B is relatively unstruc­
tured but forms a helix in the presence of TFE and calcium ions that is similar to other 
conantokin structures. These newly discovered conantokins hold promise that further 
exploration ofsmall peptidic antagonists will lead to a set ofpharmacological tools that can 
be used to characterize the role ofNMDAreceptors in nervous system function and disease.
Published by Elsevier Ltd.
A bbreviations: Gla, g, gamma-carboxyglutamate; NMDA, N-methyl-D- 
aspartate; Fmoc, N-(9-fluorenyl) methoxycarbonyl; MTBE, methyl-tert- 
butyl ether; ACN, acetonitrile; TFA, trifluoroacetic acid; ESI, electrospray 
ionization; NMR, nuclear magnetic resonance; BSA, bovine serum albu­
min; TFE, 2,2,2-trifluoroethanol; MD, molecular dynamics; DSSP, define 
secondary structure of protein.
*  Corresponding author. 257 South 1400 East, Rm. 201, Salt Lake City, 
UT 84112, USA. Tel.: +1 801 585 1868; fax: + 1 801 585 5010.
E-mail address: kigen.curtice@utah.edu (K.J. Curtice).
1 These authors contributed equally to this manuscript.
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0041-0101/Published by Elsevier Ltd.
1. Introduction
Glutamate receptors are broadly classified into two 
groups, the metabotropic receptors that transduce ligand 
binding via G protein-coupled signaling cascades and the 
ionotropic receptors that report ligand binding by opening 
an ion channel. Ionotropic glutamate receptors of the 
mammalian central nervous system are further divided 
into two subclasses, N-methyl-D-aspartate (NMDA) and
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non-NMDA receptors. NMDA receptors are hetero- 
tetrameric cation channels formed from two obligatory 
NR1 subunits and two NR2 or NR3 subunits (Schuler et al., 
2 0 0 8 ). In mammals, seven NMDA receptor subunit genes 
(NR1, NR2A, NR2B, NR2C, NR2D, NR3A, and NR3B) com­
bined with splice variants for NR1, NR2C, NR2D, and NR3A 
gene products create multiple molecular isoforms (Cull- 
Candy et al., 2001; Dingledine et al., 1999; Hollmann and 
Heinemann, 1994; Simeone et al., 2 0 0 4 ). Each isoform 
likely contributes uniquely to processes such as synaptic 
plasticity, learning, memory, and nervous system pathol­
ogies (Cull-Candy et al., 2 0 0 1 ); however, the precise role of 
each isoform is not well understood.
In combination with gene knockouts, pharmacological 
reagents provide useful tools for defining the roles of indi­
vidual NMDA receptor isoforms. To this end, small molecule 
discovery and design have provided several antagonists that 
preferentially block NMDA receptors, including N-terminal 
domain-binding allosteric modulators, such as zinc, which 
targets NR2A (Choi and Lipton, 1999; Low et al., 2000; 
Paoletti et al., 1997; Rachline et al., 2 0 0 5 ), and ifenprodil 
derivatives that target NR2B (Acklin et al., 1998; Ametamey 
et al., 2000 ; Auberson et al., 1999, 2002 ; Kinarsky et al., 
2005; Morley et al., 2005; Mosley et al., 2 0 0 9 ). In addition, 
non-competitive quinazolin-4-one derivatives, and 
competitive piperazine-2,3-dicarboxylate derivatives show 
moderate selectivity for the NR2C and/or NR2D subunits 
(Costa et al., 2009; Feng et al., 2004 ; Mosley et al., 2010). 
However, a reliable differentiating pharmacology for NMDA 
receptor subtypes is not currently available.
Conantokins are peptide inhibitors of NMDA receptors 
that are rich in gamma-carboxyglutamate (Gla) residues and 
are thought to act competitively at or near the glutamate- 
binding site on NR2 subunits (Donevan and McCabe, 2000; 
Hammerland, 1992; Sheng et al., 2009; Tsai et al., 2005; 
Wittekindt et al., 2001). Post-translationally modified Gla 
residues in conantokins are generally spaced every three to 
four amino acid residues and coordinate with divalent cat­
ions to stabilize an a-helical conformation (Blandl et al., 
2000; Chandler et al., 1993; Rigby et al., 1997; Warder et al., 
1998). Some conantokins contain appropriately positioned 
positive residues that help maintain helicity in the absence of 
metal ions (Blandl et al., 1999; Lin et al., 1997; Teichert et al.,
2007; Warder et al., 1997). All conantokins characterized to 
date either mildly or strongly prefer the NR2B subtype (Layer 
et al., 2004; Twede et al., 2009a). These NR2B-selective 
peptides, including the well-characterized conG, have 
shown significant potential in the treatment of epilepsy, 
chronic pain, ischemic stroke, and probing the mechanisms 
of drug addiction (Layer et al., 2004; Twede et al., 2009a).
Recently, conBr from Conus brettingham i was charac­
terized as a conantokin that, though having highest po­
tency for NR2B-containing receptors, exhibited relatively 
high potency for NMDA receptors containing NR2D sub­
units (Twede et al., 2009b ). Analogs of conBr highlighted 
the importance of tyrosine at position five for NR2D sub­
type inhibition (Twede et al., 2009b ). We hypothesized that 
additional examples of NR2D inhibitors might exist within 
the venoms of closely related Conus species and tested this 
by searching cDNA libraries. Several contantokins were 
identified from species in the same clade as C. brettinghami. 
In this report, we describe our results characterizing con­
antokins from Conus bocki (Fig. 1 ), particularly focusing on 
cDNA clones with the tyrosine-at-position-five character.
The phylogeny-directed search yielded eleven con- 
antokin sequences, five of which were chemically synthe­
sized and characterized. While two of these conantokins 
(conBk-D and conBk-E) were inactive on all NMDA re­
ceptors tested, the other three (conBk-A, conBk-B, and 
conBk-C) blocked NMDA receptor ion currents. Different 
from previously described conantokins, these C. bocki 
conantokins are the first identified that show a preference 
for NR2D-containing NMDA receptors. The NMDA receptor- 
inhibiting toxins are additionally distinctive in that one 
(conBk-B) is exceptionally short. These peptides provide 
proof-of-principle, showing that NR2D-blocking NMDA 
receptor antagonists exist in cone snail venom and that 
phylogeny-guided searches can facilitate identification of 
novel peptides with desirable pharmacological activity.
2. Materials and methods
2.1. Isolation o f  conantokin clones from  C. bocki
C. bocki cDNA was used as a template for polymerase 
chain reactions (PCRs) with oligonucleotides corresponding
Fig. 1. The shells of four specimens of Conus bocki from various localities in the Central Philippines. Specimens are generally collected using tangle nets at depths 
of ^ 1 0 0  m.
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to conserved regions of the signal sequence and 3' UTR se­
quences of conantokin prepropeptides. Resulting PCR 
products were purified using the High Pure PCR Product 
Purification Kit (Roche Diagnostics, Indianapolis, IN) 
following the manufacturer's protocol. DNA fragments were 
annealed to pAMP1 vector DNA and the resulting products 
were transformed into competent DH5a cells using the 
CloneAmp pAMP System for Rapid Cloning of Amplification 
Products (Life Technologies/Gibco BRL, Grand Island, NY). 
Nucleic acid sequences of resulting conantokin toxin- 
encoding clones were determined using ABI (Applied Bio­
systems) automated sequencing (Core DNA Facility, Uni­
versity of Utah).
2.2. Peptide synthesis
Peptide sequences encoded by C. bocki cDNA were 
synthesized using N-(9-fluorenyl) methoxycarbonyl 
(Fmoc)-protected amino acids. After synthesis, peptides 
were cleaved from 20 mg of resin by suspension in a 1-ml 
mixture of TFA/H2O/1,2-ethanedithiol/phenol/thioanisole 
(82.5%/5%/2.5%/5%/5% by volume) for 1.5 h at room tem ­
perature. The resulting mixture was filtered under vacuum 
into methyl-tert-butyl ether (MTBE) at - 2 0  °C. Peptide was 
collected by centrifugation at 5000  x g  for 8 min and 
washed with MTBE; centrifugation and wash steps were 
repeated three times. The resulting pellet was dissolved in 
0.1% trifluoroacetic acid (TFA)/20% acetonitrile (ACN). The 
peptide solution was applied to a Vydac C18 semi­
preparative column (10 mm x 250 mm, 5 mm particle 
size) for purification. Elution was carried out at 4  ml/min 
with use of 0.1%-TFA/10-40%ACN/H2O. Electrospray ioni­
zation (ESI) mass spectra were obtained using a Voyager GE 
STR mass spectrometer at the Mass Spectrometry and 
Proteomic Core Facility of the University of Utah.
2.3. Heterologous NMDA receptor expression in Xenopus 
oocytes
Rat NMDA receptor cDNA clones of NR1-3b, NR2A, 
NR2B, NR2C, and NR2D contained in a pSGEM vector were 
provided by Dr. Michael Hollmann from Ruhr-Universitat 
Bochum (GenBank IDs U08266, AF001423, U11419, 
U08259, and U08260, respectively). cRNA was prepared 
and purified using in-vitro RNA transcription kits (Ambion, 
Inc., St. Louis, MO) according to the manufacturer's proto­
col. For each NMDA receptor subunit cRNA, 2 -5  ng was 
injected into an oocyte using a nanoinjector. Injected oo­
cytes were incubated at 17 °C in ND-96/Pen/Strep/Ami/ 
Septra buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 
1 mM MgCl2) for 1 -6  days containing 100 units/ml peni­
cillin G, 100 mg/ml streptomycin, 100 mg/ml amikacin sul­
fate, 160 mg/ml sulfamethoxazole, and 32 mg/ml 
trimethoprim.
2.4. Electrophysiology
Voltage clamp electrophysiology was performed as 
previously described (3 6 ). Briefly, oocytes were voltage- 
clamped at - 7 0  mV and gravity perfused with magne­
sium ion-free ND-96 buffer (96.0 mM NaCl, 2.0 mM KCl,
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1.8 mM CaCl2, 5 mM HEPES, pH 7.2-7.5) with 0.1 mg/ml 
bovine serum albumin (BSA). Currents were elicited by 
one-second pulses of gravity-perfused agonist solution 
(200 mM glutamate and 20  mM glycine in magnesium ion- 
free ND96 with 0.1 mg/ml BSA). In order to determine 
appropriate agonist concentrations, glutamate concentra- 
tion-response relationships were independently deter­
mined for all four NR2 subtypes using saturating glycine 
(20 mM) (Fig. S3 ), and these showed that 20 0  mM glutamate 
elicits greater than 90% maximal response for all subtypes. 
Calcium ions were used in all ND-96 buffers to establish 
conditions similar to those thought to be important for the 
structure of conantokins under physiological conditions 
(Chandler et al., 1993; Rigby et al., 1997; Warder et al., 
1998). To rule out the possibility that Ca2+-activated chlo­
ride channels were indirectly affecting current inhibition 
by peptides, control experiments were performed with
1.8 mM Ba2+, and these demonstrated no difference in in­
hibition (Gowd et al. unpublished data). During experi­
ments, oocytes were continuously perfused in buffer with 
the exception of static bath periods during peptide 
administration. Since on- (and off-) rates of some con- 
antokins are relatively slow (Donevan and McCabe, 2 0 0 0 ), 
static bath durations were a minimum of 5 min and were 
determined empirically by the time point at which 
maximal inhibition was achieved at a given peptide con­
centration. Qualitatively, the longer peptides conBk-A and 
conBk-C had slower kinetics than the ultra-short conBk-B. 
Analyses of current recovery following removal of toxin 
provided estimates of dissociation constants (koff) ranging 
from 0.8 to 2 min-1 (see Fig. S1), meaning that a 5-min 
static bath period would be sufficient to reach at least 
97% of equilibrium even at the lowest ligand concentration 
for the slowest dissociating peptide.
NMDA receptor response at a given peptide concentra­
tion was calculated by measuring the first agonist-elicited 
response after the static bath period and then normalizing 
to baseline agonist response without peptide. For conBk-B, 
complete inhibition of NR2D-type receptors was not ach­
ieved at maximum peptide concentration. This is likely an 
experimental artifact that arises from fast off-rate kinetics of 
conBk-B paired with slow desensitization of NR2D re­
ceptors. Thus, percent response was calculated by 
comparing equivalent time points in control and test re­
sponses. Previous work has shown no significant difference 
in conantokin inhibition when measured by peak (initial) 
response compared to plateau response (> 10 s agonist 
exposure) (Wittekindt et al., 20 0 1 ). Concentration-response 
data were plotted using Prism software (GraphPad Soft­
ware, Inc., La Jolla, CA) and model curves were generated by 
fitting the normalized data to the Hill equation (% 
response =  100/{1+([conantokin]/ICs0)nH}).To test whether 
receptor subtype preferences were statistically significant, 
we applied a two-tailed, unpaired Student's t-test 
comparing IC50 values determined from multiple trials with 
no assumption concerning the equivalence of variance.
2.5. Circular dichroism (CD)
Conantokins were dissolved in 10 mM HEPES buffer (pH 
7.4) with or without 2 mM CaCl2 and with or without 60%
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2,2,2-trifluoroethanol (TFE) to a final peptide concentration 
of 100 mM. CD spectra were obtained from an average of 
five scans measured on an Aviv 62DS (Biomedical Inc., 
Lakewood, NJ) from 250 to 190 nm at room temperature. 
The molar ellipticity (9) was calculated by the following 
equation: 9 =  [100*(CD signal at 222 nm)]/[(n-1)*L*(pep- 
tide concentration in mM)] where n is the number of res­
idues, L is the cuvette path length in cm, and the 
CD signal is given in millidegrees. Helical content was 
calculated according to the following equation: % a  
helix =  100*(9222/9max), with the theoretical maximum, 
9max =  -39 ,500*(1-(2 .75/ n)).
2.6. Molecular modeling
Models of conBk-A and conBk-C were built using PyMOL 
(DeLano, 2 0 0 2 ) with a secondary structure as predicted by 
PSIPRED (Jones, 1999). Initial models were optimized using 
the LEaP module of the AmberTools package. Topology and 
coordinates of both models, conBk-A and conBk-C, were 
built with and without Ca2+ (data not shown). The resulting 
coordinates were submitted to molecular dynamics (MD) 
simulation with AMBER 9.0 (Case et al., 2 0 0 5 ) applying the 
ff99SB AMBER force field. Simulations were carried out 
using the implicit solvent model, namely the Generalized 
Born (GB) solvation model developed by Onufriev, Bashford 
and Case (GBOBC) (Bashford and Case, 2 0 0 0 ). To monitor 
conformational changes for all amino acid residues, the 
DSSP method (Kabsch and Sander, 1983) from the Ptraj 
program was used. Energy minimization involved 5000 
steps of the steepest descent (Arfken, 1985) (SD) method 
and 15,000 steps of the conjugate gradient (CG) method 
(Fletcher and Reeves, 1964). To heat up the system, a 50-ps 
MD simulation was carried out using an initial temperature 
o f2 5 0  K and a final temperature of 298 K. Neither restraints 
nor constraints were applied during the heating step. Next, 
a 1.25-ns MD simulation with 2-fs time steps was per­
formed. The temperature was maintained at 298 K with 
Berendsen coupling (Berendsen et al., 1984) and a 10-A 
cutoff was applied.
2.7. NMR spectroscopy
HPLC-purified conBk-B peptide was resuspended in 
NMR buffer to yield final concentrations of 10 mM MES 
(13D) pH 6.1, 40% TFE, and 1.13 mM peptide. Peptide con­
centration was determined by absorbance measurement at 
280 nm, using an extinction coefficient for the single 
tyrosine residue of 1280 cm -1 M-1. Calcium ion titrations 
were performed by adding small volumes of 0.1 M calcium 
chloride dissolved in NMR buffer at early titration points 
and 1 M calcium chloride dissolved in NMR buffer at later 
titration points. A mock titration using identical solutions, 
but without conBk-B peptide, showed that pH was altered 
less than 0.1 pH unit from start to end points of the calcium 
titration, indicating chemical shift changes are a result of 
Ca2+ binding and not changes in pH. Following titration, the 
sample was used for 2D NMR experiments with final so­
lution conditions: 10 mM MES (13D) pH 6.1,11 mM CaCl2, 
40% TFE, and 1.10 mM peptide. Additional Ca2+ ion
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titrations were measured in the absence of TFE, but 
otherwise similar conditions.
One dimensional [ 'h ]  proton spectra and two­
dimensional [13c , 'h ]  h s q c , [ 'h , 'h ]  cosy , [ 'h , 'h ]  to c s y , 
and ['H, 'h ]  NOESY spectra were recorded at 20 °C on a 
Varian Inova 600 MHz spectrometer with a cryogenic 
probe. Data were processed with FELIX2004 and analyzed 
using SPARKY (T. D. Goddard and D. G. Kneller, University of 
California, San Francisco). The solution structure of calcium 
ion-bound conBk-B was determined from 82 NOE distance 
constraints using NIH-XPLOR (Schwieters and Clore, 2001; 
Schwieters et al., 2 0 0 3 ). Starting with a linear template, 
simulated annealing generated 100 structures with 
convergence in backbone architecture and variation in side 
chain rotamers. To control for potential effects of side chain 
rotamer in subsequent steps, four low-energy structures 
that sampled all side chain rotamers were selected to seed 
refinement in NIH-XPLOR. Each of these four structures 
seeded a separate refinement protocol in NIH-XPLOR to 
generate a total of 1000 structures. The five lowest-energy 
structures from each of the four refinements were com­
bined to create the final 20-structure ensemble. Atomic 
coordinates and NMR data were deposited with the Protein 
Data Bank as entry 2m 7r.
Mathematical modeling of Ca2+ ion titration data was 
accomplished with CALCIUM04, a C language program 
(M.P.H.) which implements the least-squares Marquardt 
algorithm (Marquardt, 1963) to fit parameter values. 
Adjustable parameters describing the system were the 
intrinsic dissociation constant at each of two binding sites 
(Kdi and Kd2 ), a cooperativity parameter (Kcooperativity), and 
changes in chemical shift values for binding Ca2+ at site 1 
(ASi) and at site 2 (AS2). All data were fit with global values 
for KD1, KD2 , and Kcooperativity, and nuclei-specific values for 
AS' and AS2. To avoid over-parameterization, changes in 
chemical shift were assumed to be additive, meaning that 
the final change in chemical shift observed with both sites 
occupied was taken as AS' +  AS2. ConBk-B was described as 
a partition with four possible states: no Ca2+ ions bound 
(p00), site 1 occupied (p01), site 2 occupied (p10), and both 
sites occupied (p n ). Partition values and fraction of free Ca2+ 
ions (c =  [Ca2+f-ee]/[Ca2+total]) were obtained by numerical 
methods so as to satisfy the following system of equations:
n =  nc +  p01 +  p10 +  2pii (1 .1)
1 =  p00 +  p0i +  p10 +  p11 (1 .2)
Kdi /  Ptotal =  ncpaa/ p0i (1.3)
KD2 / Ptotal =  ncp00/p10 (1 4 )
KD1KD2Kcooperativity/P total =  n c2p00/p11 (1 .5)
where Ptotal is the total peptide concentration, and n is the 
ratio [Ca2+total]/Ptotal, which is a known quantity. Equations 
(1.1) and (1.2) describe conservation of mass forcalcium ions 
and peptide respectively. Equations (1.3)-(1.5) describe
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three equilibria: dissociation at site 1, dissociation at site 2, 
and simultaneous dissociation at both sites. Uncertainties in 
parameter values were estimated with a bootstrap method 
that repeated curve-fitting analysis for several simulated 
data sets, with each simulated data set derived by sampling 
from the experimental data with replacement.
3. Results
3.1. Identification o f  C. bocki clones encoding conantokins
Conantokin sequences were identified from cDNA 
clones of mRNAs isolated from the venom duct of C. bocki 
(Fig. 1 ). This species belongs to the clade Asprella that also 
comprises C. brettinghami, Conus sulcatus, Conus rolani, and 
Conus sam iae . Since previous work established that a 
tyrosine residue at position five was important for high 
potency towards NMDA receptors with NR2D subunits
(Twede et al., 20 0 9 b ), we focused on such examples found 
for C. bocki conantokins, although additional sequences not 
containing tyrosine at position five were also cloned. The 
nucleotide sequences, predicted translation products, and 
mature peptide sequences of five C. bocki peptides are 
shown in Table . Post-translational modification of gluta­
mate residues to g-carboxyglutamate is well established for 
the conantokin family (Jimenez, 2 0 0 9 ). Five glutamate 
residues in conBk-A, conBk-C, and conBk-D and three of the 
glutamate residues in conBk-B and conBk-E were predicted 
to be modified to g-carboxyglutamate. Predicted mature 
peptide sequences were synthesized for conBk-A (22 AA), 
conBk-B (9 AA), conBk-C (18 AA), conBk-D (19 AA) and 
conBk-E (9 AA). Interestingly, the predicated mature se­
quences for conBk-B and conBk-E are only 9 residues in 
length and represent the shortest conantokin sequences 
identified to date. Of course, it remains to be demonstrated 
that these peptides are present in injected venom, but this
Table 1
Nucleotide and amino acid sequences of cloned Conus bocki  conantokins.
Conantokin Nucleotide and predicted amino acid sequences a
conM -A
CACAGAGGCGATGAAGAATATTCAGAGTTTATAGAGAGAGAACGCGAACTCGTCAGTTCTAAAATCCCCAGATAG
H R G D E E Y S E F I E R E R E L V S S K I P R
conBfc-B GCCAGAGGCGAAGAAGAATATTCAGAGGCTATAGGAAGAAAATAA
A R G E E E Y S E A I G R K
conBk-C GCCAGAGACGATGAAGAATATGCAGAGTTTATAGAGCAACAACGCGAAGCAGGATTAGTGTAA
A R D D E E Y A E F I E Q Q R E A G L V
con5fc-D GCCAGAGGCAAAGAAGAACTTGCAGAGAACGCGCCGGAGTTTGCCAGAGAACTAGCTACAAATGGAAAAAGATAA
A R G K E E L A E N A P E F A R E L A T N G K R
conB£-E GCCAGAGGCGAAGAAGAATGTTCAGAGGCTATAGGAAGAAAATAA
A R G E E E C S E A I G R K
Conantokin Predicted mature amino acid sequences b
conM -A G D yy Y S y  F l y  R E R y L V S S K I P R A
conBfc-B G E y y Y S y  A l *
conM -C D D y y Y A y  F l y  Q Q R y  A G L V A
conM -D G K y y  L A y N A P y  F A R y  L A T N *
con5£-E G E y y C  S y  A l *
conflrc G D y y Y S K F I y  R E R y A G R L D L S K F P A
conCr* G E y y L Q y  N Q y  L I R y  K S N *
caoT G E y y Y Q K M L y  N L R y  A E V K K N A *
y  G la residues.
A, C O O H ; * ,  CO N H 2
a predicted cleavage site for mature toxins are shown in bold and stop codons are underlined 
b conserved and predicted gla residues are highlighted 
c Twede et a l, 2009 
d Mena et ah, 1990 
e Haack et al., 1990
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Fig. 2. Relative potencies of conantokins from Conus bocki tested on NMDA 
receptors. One of the four NR2 subunits was co-expressed with NR1-3b in 
Xenopus oocytes. Concentration-response relationships obtained utilizing 
two-electrode voltage clamp electrophysiology are shown for conBk-A (A), 
conBk-B (B) and conBk-C (C). Each data point represents the average peak 
current response from a minimum of three independent oocytes. Error bars 
represent ±  SEM. These three conantokins from C. bocki showed the highest 
potency on receptors with the NR1-3b/NR2D subunit combination 
(diamonds).
seems likely to be the case as the clones were derived from 
mRNA isolated from the venom duct.
3.2. Functional characterization o f  conantokins from  C. bocki
Peptides were functionally assessed using two- 
electrode voltage-clamp electrophysiology in Xenopus o o ­
cytes coexpressing a single NR2 subunit with the NR1-3b
subunit. Example recordings from these experiments are 
provided in the supplementary information, Fig. S1. Dose- 
response curves are shown in Fig. 2 , and IC50 values are 
summarized in Table 2 . ConBk-D and conBk-E were inactive 
at all concentrations tested. ConBk-A, conBk-B, and conBk-C 
were active and interestingly, exhibited highest potency for 
NR2D subunits. ConBk-A and conBk-C blocked NR2D- 
containing NMDA receptors with IC50 values of 0.46 
(±0 .04 ) mM and 0.17 (±0 .02 ) pM, respectively. The shorter 
peptide, conBk-B, was 10-fold less potent on all NMDA re­
ceptor subtypes compared to the larger counterparts, yet 
retained NR2D preference with an IC50 value of 1.9 pM. 
Though the preference for NR2D over other receptors was 
modest, differences in IC50 values were statistically signif­
icant (p < 0.05) for both conBk-B and conBk-C (Table S1).
3.3. Sequence determinants o f  NMDA receptor inhibition by 
conBk-B
The short length of conBk-B and its preference for 
NMDA receptor subtypes containing the NR2D subunit 
motivated experiments to elucidate determinants of sub­
type selectivity. ConBk-E differs from conBk-B by substitu­
tion of tyrosine 5 with cysteine and is thus a naturally 
occurring single amino acid substitution variant. Inactivity 
observed for conBk-E demonstrates the importance of po­
sition five. We also considered the possibility that conBk-E 
may covalently form a homodimer via cys-5; however, no 
activity was subsequently observed in a dimerized form of 
conBk-E (not shown). We designed and synthesized addi­
tional sequence analogs of conBk-B and conBk-C to test the 
importance of other sequence determinants. Table 3 shows 
amino-acid sequences for conBk-B, conBk-E, and designed 
analogs; Table 4 shows the corresponding IC50 values. 
Removing C-terminal amidation from the naturally occur­
ring conBk-B sequence (conBk-B[COOH]) rendered the 
peptide inactive, suggesting amidation may stabilize the 
active conformation or interact with NMDA receptors. The 
analog constructed with the first nine residues of conBk-C 
(conBk-C [1-9]) was not active on any of the NMDA receptor 
subtypes tested, indicating only certain amino acid com­
binations are tolerated in a nine residue scaffold.
To test sequence permutations we constructed nine- 
residue chimeric conantokins with amino acids derived 
from conBk-B and conBk-C. The first nine residues of these 
two conantokins differ at positions 1, 2, 6, and 8. Chimer- 
aBk-BC [1-9] contains amino-acid residues derived from 
conBk-B at positions 1 -2  and amino-acid residues derived 
from conBk-C at positions 6 and 8, and showed inverted 
preferences for NR2B and NR2D, meaning that this chimera 
is more similar to previously characterized conantokins in 
its preference for NR2B over NR2D. Note that this chimera 
terminates with a free carboxylic-acid functional group and 
retains activity, indicating an amide protecting group is not 
absolutely required for NMDA receptor inhibition. Chi- 
meraBk-CB [1-9] swaps conBk-B and conBk-C derived 
amino acids in the converse manner, with conBk-C residues 
at positions 1 - 2  and conBk-B at positions 6 and 8, and 
resulted in an inactive peptide. A point mutation at position 
eight (conBk-B [A8F]) resulted in loss of preference for 
NR2D containing receptors, suggesting that residue 8 may
72
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Table 2
Comparison of IC50 values measured for Conus bocki conantokins and others.
NMDA receptor subtype IC50 value ±  SEM (mM) [hill coefficient] IC50 ratio
NR2A NR2B NR2C NR2D D/B A/B C/B
conBk-A 0.9 ±  0.3 [—1.9] 0.92 ±  0.07 [—1.9] 1.4 ±  0.2 [—1.1] 0.46 ±  0 .0 4 [ —1.5] 0.50 0.92 1.5
conBk-B 3.9 ±  0 .2 [ —1.3] 5.1 ±  0.2 [—1.2] 3.9 ±  0.1 [—0.8] 1.91 ±  0.06 [—0.9] 0.37 0.76 0.76
conBk-C 0.9 ±  0.1 [—1.4] 0.37 ±  0.07 [—1.6] 1.5 ±  0 .0 7 [ —1.2] 0.17 ±  0.02 [—0.93] 0.46 2.5 4.1
conR/-A 0.52b 0 .1 1 b 6 .1 b 0.48b 4.4 4.7 55
conG > 1 0 c 0 .1 c 1c 1c 1 0 - 1 0 0 10
conR 0.53a 0 .35a - 1 0 a - 1 0 a - 3 0 1.5 - 2 9
Ratios in bold are the extrem es; in combination, two conantokins with extrem e ratios may help discriminate between NR2 subtypes specified in each 
column. IC50 values w ere determined using a curve fit o f data from n =  3 - 6  oocytes. Standard error of mean (SEM) was determined by analysis ofIC50 values 
calculated from individual experimental trials. ConBk-D and conBk-E  w ere inactive at concentrations tested. 
a Twede et al., 2009a,b. 
b Gowd et al., 2 0 1 0 . 
c Teichert et al., 200 7 .
Table 3
Amino acid sequences of conBk-B  and analogs.








y Gla residues. 
a C-terminal amidation. 
b C-terminal carboxyl.
contact a region that differs between NMDA receptor sub­
types. In summary, short conantokin analogs require 
conBk-B-like sequences in the amino-terminal portion for 
activity, and changes in carboxy-terminal residues strongly 
affect either activity or subtype selectivity.
3.4. Circular dichroism
Conantokins are relatively unstructured yet acquire 
helicity in the presence of divalent metal ions (Blandl et al., 
2 000 ; Chandler etal., 1993; Rigby et al., 1997; Warder et al.,
1998). Helical content of C. bocki conantokins was assessed 
by circular dichroism spectroscopy in both the presence 
and in the absence of Ca2+ (Fig. 3 ). In the absence of Ca2+ all 
three peptides had no apparent helical structure, a result 
consistent with other conantokins. In the presence of Ca2+, 
however, conBk-A and conBk-B retained low helical con­
tent, whereas conBk-C adopted significant helicity.
Table 4
IC50 values measured for conBk-B analogs.
ConBk-A and conBk-B appear to be the first NMDA 
receptor-inhibiting conantokins to exhibit little or no hel- 
icity in the presence of Ca2+ ions. To test if the shortest 
conantokin, conBk-B, can acquire helical structure in a 
stabilizing solvent, the effect of 2,2,2-trifluoroethanol (TFE) 
was examined (Fig. 3 ). Upon addition of 60% TFE to peptide 
in a Ca2+-free solution the helical content of conBk-B 
increased from 2 to 24 percent and upon addition of 60% 
TFE to peptide in solution containing Ca2+, helical content 
increased from 5 to 43 percent. The results suggest that 
conBk-B can coordinate Ca2+ ions to adopt a helical struc­
ture, albeit more weakly or with faster exchange kinetics 
than other conantokins.
3.5. Molecular modeling
To explain the differences of Ca2+-stabilized helical 
content between conBk-A and conBk-C, we applied mo­
lecular modeling (see Fig. S2 ). Molecular dynamics simu­
lations show the secondary structure of conBk-C without 
Ca2+ ions was a short helix between residues 6 -9  with a 
percentage occurrence of 7%. The presence of Ca2+ changed 
this observation and resulted in two helices spanning res­
idues 2 -5  and 12-15 with a percentage occurrence of 70%. 
In the case of the conBk-A, we observed one helical region 
between residues 13-17, which did not change in location 
but did increase in percent occurrence from 4% to 50% upon 
addition of Ca2+ in the MD simulations. We quantified 
helix-stabilizing interactions as Ca2+ bridges between 
negatively charged groups. For conBk-C these are Asp1- 
Ca2+-Tyr5 (via p-electrons of the Tyr), Asp1-Ca2+-Gla4,
NMDA receptor subtype IC50 values ±  SEM (uM) [hill coefficient] NR2D/NR2B
IC50 ratios
NR2A NR2B NR2C NR2D
conBk-B 3.9 ±  0.2 [ — 1.3] 5.1 ±  0.2 [—1.2] 3.9 ±  0.1 [—0.8] 1.91 ±  0.06 [—0.9] 0.37
conBk-E > 1 0 > 1 0 > 1 0 > 1 0 ND
conBk-B[COOH] > 1 0 > 1 0 - > 1 0 ND
conBk-C [1-9] > 1 0 > 1 0 > 1 0 > 1 0 ND
conBk-B[A8 F] > 1 0 2.1  ±  0 .6  [—1 .0 ] - 2.9 ±  0 .3 [ —1.3] 1.4
chimeraBk -BC [1-9] > 1 0 3.3 ±  0.6 [— 0.7] - 6 .2  ±  0 .2 [—1 .0 ] 1.9
chimeraBk -CB [1-9] > 1 0 > 1 0 - > 1 0 ND
Each IC50 value represents the average from n =  3 - 6  oocytes.
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Fig. 3. CD spectra of conBk-A, conBk-B, and conBk-C. A. CD spectra for conBk- 
A and conBk-C in the presence and absence of 2 mM CaCl2. B. CD spectra for 
conBk-B without CaCl2, with 2 mM CaCl2, 60% TFE, or both 2 mM CaCl2 and 
60% TFE. The dual minima at 208 and 222 nm are characteristic of an a- 
helical conformation. Ellipticity is plotted on a per-peptide bond basis to 
simplify comparison of these conantokins that vary in length. Data points 
represent the average of 5 independent scans.
Gla4-Ca2+-Tyr5, Gla4-Ca2+-Gla7, Gla3-Ca2+-Gla4, Gla3- 
Ca2+-Gla7, Asp2-Ca2+-Gla10, Asp2-Ca2+-Gla14, and Gla10- 
Ca2+-Gla14. And for conBk-A these are Gla3-Ca2+-Gla4, 
Gla7-Ca2+-Gla14, Gla7-Ca2+-Gla10, and Gla10-Ca2+-Gla14. 
More numerous calcium ion-bridging interactions 
observed for conBk-C is consistent with higher helicity 
observed by CD spectroscopy. The sequence alignment 
presented in Table 1 shows an Arg-Glu-Arg structural motif 
(residues 11-13) in conBk-A. In the case of conBk-C, corre­
sponding residues are Gln-Gln-Arg. The MD simulations 
suggest the presence of positively charged Arg11 situated 
adjacent to negatively charged Gla10 interrupts helical 
structure in conBk-A. Presumably, the mutation conBk-A 
[R11Q] would increase helicity of the peptide in the pres­
ence of calcium ions, however this prediction is yet to be 
tested.
3.6. NMR spectroscopy o f  conBk-B
To date, conBk-B is the shortest conantokin to be 
detected in cDNA libraries and also selects for NR2D over 
NR2B more so than any other known conantokin. For these 
reasons, we were motivated to characterize the structural 
behavior of this ultra-short conantokin. Resonances from 
1H and 13C nuclear spins were assigned from 2D NMR 
spectra obtained with natural abundance samples (Fig. 4 (A) 
and (B)). To determine the relative contributions of calcium 
ions and TFE for helical structure in conBk-B, we examined
Fig. 4. NMR data for conBk-B. (A) Amide-alpha proton (HN-HA) region of 
the 2D NOESY spectra recorded for conBk-B shows complete residue con­
nectivity (red dotted lines). NOEs from HA atoms of Gly-1 are indicated by 
asterisk (*). Multiple i to i+3 HA/HN NOEs can be seen, consistent with an a  
helix. (B) Amide-aliphatic-aromatic proton region of the 2D NOESY spectra 
shows NOEs between Tyr-5 and Ile-9, indicating proximity for these side 
chains within the structure of conBk-B. (C) Effects of calcium ions and TFE on 
conBk-B structure. Changes in 13Ca chemical shifts (A8) were obtained by 
subtracting the chemical shift values observed in buffer with no added 
calcium salt and no added TFE. Positive values of A8 indicate increased 
helical content due to addition of 10 mM CaCl2 (blue), 40% TFE (green), and 
both calcium and TFE (yellow). (For interpretation of the references to color 
in this figure legend, the reader is referred to the web version of this article.)
13Ca chemical shifts in 2D CHSQC spectra. Fig. 4 (C) shows 
differences in conBk-B 13Ca chemical shifts measured upon 
addition of 11 mM calcium chloride (10 peptide equiva­
lents), addition of 40% TFE, and the combination of adding 
both calcium chloride and TFE. Calcium ion addition moved 
chemical shifts downfield by 0 .07 -0 .48  ppm for all residues 
except Gla-7, which was essentially unperturbed. Down- 
field perturbations for 13Ca nuclei are consistent with a 
shift in structural equilibrium towards an a  helix. TFE 
produced significantly larger downfield shift changes 
ranging from 3.56 to 5.14 ppm. The combined effect of 
calcium ions and TFE generally resulted in larger downfield 
chemical shift changes ranging from 3.54 to 5.6. The data
74
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indicate that calcium weakly promotes helical structure 
and its effects are additive to those of TFE, which strongly 
promotes helical structure in conBk-B.
Calcium ion binding of conBk-B was assessed by tracking 
proton chemical shift changes from 1D NMR spectra during 
a titration. Fig. 5 shows proton chemical shift plotted as a 
function of Ca2+ concentration for amide and gamma pro­
tons of conBk-B dissolved in 40% TFE. Many protons showed 
a simple monophasic response to titration with calcium 
ions, but Gla-4 and Tyr-5 amide protons responded in a 
biphasic manner, moving upfield with initial increases in 
calcium ion concentration and moving downfield at later 
stages of the titration, suggesting there are two Ca2+- 
binding sites with differing affinities.
We considered several versions of a two-site binding 
model. One model assumed no interaction between sites, 
and other models assumed either positive or negative
Fig. 5. Calcium binding to conBk-B monitored by NMR. Chemical shifts were 
obtained from ID NMR spectra measured for conBk-B peptide solutions at 
20 °C containing 40% TFE and varying concentrations of calcium chloride. 
Response of each amide proton is plotted with the following symbols: +  Glu 
2, o Gla-3, Gla-4, x Tyr-5, a Ser-6, Gla-7, V  Ala-8, Ile-9. Gamma 
proton chemical shifts for the three Gla residues in conBk-B are plotted with 
symbols: Gla-3, Gla-4, and ^  Gla-7. Model curves depict the result of 
non-linear least-squares fitting of these data (and other data not shown) 
with global parameters that define a system of two calcium-binding sites 
with differing intrinsic affinities and modest positive cooperativity between 
sites.
interaction. The independent sites model adequately 
accounted for all of the data, but had larger residuals than a 
model with positive cooperativity. A model with negative 
cooperativity did not fit data well and was not considered 
further. The independent sites model and the positively 
interacting sites model yielded the same intrinsic dissoci­
ation constant for the high-affinity binding site 
[KD1 =  0 .31(±0.03) mM] and comparable values for the 
low-affinity binding site [KD2 =  2 .8(±0.5) mM for inde­
pendent sites; KD2 =  4 (± 1 ) mM for cooperative sites]. 
Interaction between Ca2+-binding sites was described by a 
parameter (Kcooperativity) that is the ratio of apparent 
dissociation constants for a given site with the second site 
occupied (numerator) and unoccupied (denominator). This 
parameter refined to a value of Kcooperativjty =  0.6(±0.2), 
indicating the affinity at each binding site appeared to in­
crease 1.67-fold with occupancy at the other site. This 
corresponds to -1 .4 (± 0 .7 )  kJ mol-1 of binding energy that 
is realized when both sites are occupied. Two homoge­
neous sites with a similar degree of interaction would 
exhibit a Hill coefficient of n =  1.14. Comparable calcium ion 
titrations, with similar midpoints and biphasic responses, 
were also measured without TFE. Curve fitting analyses of 
these titrations obtained in the absence of TFE could be 
accomplished with the same dissociation constants defined 
by data measured with TFE.
3.7. NMR structure determination
The calcium ion-bound structure of conBk-B stabilized 
with the cosolvent trifluoroethanol was determined by 2D 
NMR spectroscopy using natural abundance 1H and 13C 
nuclear spins. Complete resonance assignments were ob­
tained through examination of NOESY, TOCSY, and CHSQC 
spectra. The NOESY spectra had 82 NOE resonances with 
signal to noise greater than 10, and these contained 63 
short-range [i:i, i:i+1] and 19 medium-range [i:i+2, i:i+3, 
or i:i+4] distance constraints. The fingerprint region of the 
NOESY spectra (Fig. 4 (A)) showed sequential HN-Ha con­
nectivity and contained i:i+3 cross peaks (Ha-HN) consis­
tent with an a helix. Additional evidence of a-helical 
structure was seen in 16 of the 19 medium range NOEs 
between residue side chains. For example, side chain pro­
tons of Tyr-5 and Ile-9 had cross peaks indicating proximity 
(see Fig. 4 (B)).
Fig. 6(A) shows the ensemble of energy minimized 
conBk-B structures as short a helices. Ensemble members 
were aligned with main chain atoms (Ca, N, HN, C, O) of 
residues 3 -9 , since these adopted more consistent posi­
tions than those of residues 1 and 2. The alignment yielded 
a root-mean-squared deviation of 1.6 A for all atoms of all 
residues, 1.1 A for all main chain atoms of all residues, and 
0.5 A for main chain atoms of residues 3 -9 . The three Gla 
residues of conBk-B cluster along one face of the helix, 
apparently poised to coordinate Ca2+ ions (Fig. 6(B) and 
(C)). A glutamate residue at position 2 (Glu-2) is on the 
opposite face of the helix and is therefore unlikely to 
contribute directly to high-affinity Ca2+ binding. Hydro­
phobic residues Tyr-5 and Ile-9 are grouped at the C-ter­
minal half of the helix and are found on the face opposite to 
the Gla residues. The hydrophobic contacts involving Tyr-5
75
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Fig. 6. ConBk-B NMR structure. (A) Twenty energy-minimized structures, shown with colored tubes, highlight the helical conformation of conBk-B. (B) An 
ensemble of energy-minimized conBk-B structures is shown with all-atom stick models in stereo. Atoms are color coded as follows: H white, C charcoal, O red, N 
blue. For clarity, only ten (of twenty available) randomly selected models are shown. A representative model, selected because it most closely resembles the 
ensemble average, is highlighted with thicker sticks. (C) ConBk-B is approximately amphipathic with respect to two perpendicular axes (dotted lines). Charged Gla 
and other polar moieties are clustered at the N-terminal half of conBk-B and along one face of the helix, while more hydrophobic residues are grouped together at 
the C-terminal half of the opposite face. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
probably augment helix stabilization provided by salt 
bridges between carboxylate groups and calcium ions.
We compared the conBk-B structure to structures of 
conG and conT, two longer conantokin toxins previously 
characterized by NMR structure determination (Skjaerbaek 
et al., 1997). Representative models of each conantokin are 
shown in Fig. 7. The three structures share identical N- 
terminal residues 1-4 and the structures align fairly well in 
this region. The most striking difference between the three 
structures is overall length, with conBk-B shortest (9 resi­
dues), conT longest (21 residues), and conG in the middle 
(17 residues). ConBk-B and conG have very similar orien­
tations for Gla-3, Gla-4 and Gla-7 (highlighted in Fig. 7 with 
red dots), suggesting these two peptides coordinate cal­
cium ions in a similar manner. ConBk-B and conT have 
highly comparable orientations for Tyr-5, which makes 
hydrophobic contacts with residue nine in both structures. 
In the structural comparison, amino-acid position 8 
(highlighted in Fig. 7 with black dots) stands out as having 
the largest variation in volume and shape while located in 
an otherwise conserved region. Amino-acid identity at
position eight is an important determinant of selectivity in 
conantokins as shown by the A8F replacement variant (see 
Table 4) and by previous studies (Sheng et al., 2007, 2010). 
The structural differences highlighted here additionally 
corroborate the idea that this residue position may hold the 
key for future design of increasingly selective conantokins.
4. Discussion
A discovery strategy incorporating inferences based on 
phylogenetics and previous structure-function studies led 
us to the identification of conBk-A, conBk-B, conBk-C, 
conBk-D and conBk-E from C. bocki. Molecular phylogeny as 
a means to targeted drug discovery, also known as exoge­
nomics, has been described and successfully applied to 
discover Conus toxins with novel pharmacological proper­
ties (Bulaj, 2008; Olivera, 2006; Olivera and Teichert, 2007; 
Teichert et al., 2007). In the present case we were searching 
for conantokins that were potentially active on NR2D- 
containing NMDA receptors and identified C. bocki as a 
possible source because of its close phylogenetic relation to
Fig. 7. Comparison of conantokin structures determined by NMR. Representative models of conBk-B (A) [9 residues, pdb id 2m7r], conG (B) [17 residues, pdb id 
1onu], and conT (C) [21 residues, pdb id 1ont] were aligned by superposition of residues 3-9. All three structures are a-helices, depicted here as stick models 
inside semi-transparent accessible surfaces. Gla residues (highlighted with red dots) are positioned along a nearly contiguous ridge for conBk-B and conG and 
appear more distributed for conT. Differences in side chain volume at position 8 (highlighted with black dots) may contribute to NMDA receptor subtype 
selectivity. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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C. brettinghami, previously the source of the most NR2D- 
potent conantokin (conBr) (Twede et al., 2009b). As could 
be predicted from structure-function studies of conBr an­
alogs (Twede et al., 2009b), the three peptides derived from 
C. bocki that contained tyrosine at position five showed 
inhibition of NMDA receptors with NR2D subunits. Unex­
pectedly, all three peptides additionally had decreased 
inhibitory activity for NMDA receptors with NR2B subunits 
compared to previously described conantokins. Discovery 
of peptides with decreased potency in block of NR2B con­
taining receptors was, in a sense, a bonus that could not 
have been predicted a priori, and is sure to guide future 
iterations of the exogenomics approach.
ConBk-D and conBk-E, although inactive in our assays, 
provide insights into sequence determinants for NMDA 
receptor inhibition that complement previous insights 
derived from structure activity work. For instance, alanine 
scanning in conG, conT, and conR highlighted the impor­
tance of residues at positions two and five for activity 
(Blandl et al., 1998, 2001; Warder et al., 2001). Data ob­
tained in the present study suggests that the positive 
charge on lysine at position two, of conBk-D, abolishes 
antagonist activity for NMDA receptors tested here. Also, 
comparison of conBk-E with conBk-B shows that substitu­
tion of a cysteine side chain at position five renders the 
short peptide scaffold inactive.
Previous work showed that native conantokins can lose 
biological activity as they are shortened (Blandl et al., 1998, 
2001; Warder et al., 2001). The discovery of conBk-B 
encoding mRNAs in venom ducts strongly suggests that 
ultra-short conantokin peptides with NMDA receptor 
inhibitory activity exist in the natural world. Sequence 
permutations evaluated in this study showed that only 
certain combinations of amino acids in the nine-residue 
scaffold retain activity. Surprisingly, some permutations 
switched peptide preference for receptors between NR2B 
and NR2D subtypes, suggesting that a few contacts provide 
distinction between these NMDA receptor homologs. Most 
critical for selectivity are residues at positions 5,6, and 8, as 
previously identified in other conantokins (Sheng et al., 
2007, 2009, 2010). Thus, this ultra-short peptide likely in­
teracts with receptors utilizing the same mechanism as its 
larger counterparts. Interestingly, the structural compari­
son of conBk-B to conG and conT independently highlighted 
position 8 as a possible determinant of subtype selectivity 
(see Fig. 7).
Our structural analysis suggests that a calcium ion- 
stabilized helical conformation is not necessary for recep­
tor inhibition, consistent with the observation that conG 
and conT inhibition of MK-801 binding in rat brain is not 
hindered by the addition of EDTA (Klein and Castellino,
1999). In our analysis, ConBk-A and conBk-B showed little 
helical content in the presence of calcium ions, yet had 
inhibitory activity comparable to other, more helical con- 
antokins. NMR spectroscopy verified the unstructured state 
of conBk-B through absence of mid-range NOEs for peptide 
in the presence of calcium ions. These mid-range NOE's 
were, however, present when the co-solvent TFE was 
included. Conantokins likely adopt a unique conformation 
upon receptor binding so as to maximize contacts between 
peptide and receptor. This receptor-bound state may be
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similar to helical structures of conG, conT, and conBk-B in 
solution, but is probably a structurally distinct conforma­
tion that may or may not require calcium ions. Thus, a 
major focus of our future research is to determine the re­
ceptor interface and conformation of a receptor-bound 
conantokin.
An important achievement of this work was to 
demonstrate a measure of NR2D preference for peptide 
based NMDA receptor antagonists, which makes investi­
gation of the role of these subunits in physiological systems 
using a pharmacological approach more feasible. The NR2D 
subunit has a relatively restricted expression pattern that is 
enriched in midbrain, spinal, and peripheral structures, 
such as the substantia nigra, striatum, dorsal horn, and 
dorsal root ganglia (Counihan et al., 1998; Hummel et al., 
2008; Karlsson et al., 2002; Kosinski et al., 1998). Thus, 
NR2D may play a functional role in pathological conditions 
that affect these regions, such as Parkinson's disease and 
chronic pain. Although limited work has been done, NR2D 
knockout studies support this hypothesis (Micu et al., 
2006; Minami et al., 2001).
NR2D-containing NMDA receptors additionally have 
unique physiological properties, including decreased 
sensitivity to magnesium blockade and prolonged deacti­
vation kinetics (Cull-Candy et al., 2001), which implicates 
involvement of the NR2D subunit in excitotoxicity. Recent 
work suggests that NR2D (or NR2C) is involved in excito- 
toxic damage to myelin sheaths following ischemia (Micu 
et al., 2006), and may participate in the underlying mech­
anistic basis for excitotoxic neuronal loss in prion diseases 
(Khosravani et al., 2008). Subsequently, selective blockage 
or modulation of NMDA receptor activity should promote 
neuron survival in these patients if the hypotheses are 
correct. Motivated by these potential applications, we can 
now initiate structure-function studies to enhance NR2D 
selectivity of conantokin peptides through modification of 
the newly discovered NR2D-preferring C. bocki toxins.
In order to investigate the role of NMDA receptor sub­
types, we envision use of peptide combinations that can 
provide a measure of pharmacological differentiation be­
tween pairs of NMDA receptor subtypes. Such a strategy of 
using pairs of conopeptides has recently been used for 
differentiating between different voltage-gated sodium 
channel subtypes (Wilson et al., 2011). To take a particular 
example in the context of NMDA receptor discrimination, 
the combination of conBk-B and conR could, in principle, 
discriminate between NR2B and NR2D containing re­
ceptors. ConR is similarly active on NR2B and NR2A con­
taining receptors and inactive on NR2C and NR2D (Table 2). 
ConBk-B is most active on NR2D containing receptors with 
varying but lower activity on NR2C > NR2A > NR2B. The 
contrasting effects of these peptides could therefore be 
compared in experimental paradigms to provide insight 
into the relative abundance of NR2B and NR2D NMDA re­
ceptor subunit combinations present in various physio­
logical contexts. Similarly, combining conBk-B with conG 
would be expected to provide more than a two order of 
magnitude difference in selectivity between the NR2A and 
NR2D subtypes. Even NR2C versus NR2B containing NMDA 
receptors might be distinguished by using conBk-B 
together with conRl-A. Although single pharmacological
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agents to discriminate between the different NMDA re­
ceptor subtypes are preferable, the discovery of conBk-A, 
conBk-B, and conBk-C provides an initial basis for devel­
oping peptide-based differentiating pharmacology for the 
NMDA receptor receptor family.
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CHAPTER 3
THE NMR SOLUTION STRUCTURE OF CONANTOKIN RL-B
Introduction
Conantokins are unique among conotoxins in sequence, structure, and function. 
Most conotoxins are rich in cysteine residues, have tertiary structures stabilized through 
disulfide bonds, and are effectors of various voltage- and ligand-gated ion channels. In 
contrast, conantokins are rich in y-carboxyglutamate (gla) residues, have tertiary structures 
stabilized by coordination of calcium ions, and are the only conotoxins discovered to date 
that inhibit N-methyl-D-aspartate receptors (NMDARs)1-3. In the absence of calcium, most 
conantokins are unstructured as evidenced by circular dichroism (CD) and nuclear magnetic 
resonance (NMR) experiments4-7. Addition of calcium results in conformational changes in 
conantokins as gla residues align along a single face to coordinate calcium ions. Alignment of 
gla residues drives conantokins to adopt a helical conformation. The degree to which helicity 
increases with calcium varies among conantokins, and is dependent on sequence 
characteristics such as gla residue spacing and the presence of positively charged residues 
that appear to augment helix stability8,9. Figure 3.1 illustrates the calcium-driven 
unstructured-to-helical transition by comparing NMR structures of conantokin-G (conG), 
determined in the absence and presence of calcium ions10,11.
Structure-function studies on conantokins indicate that residues on the amino- 










Figure 3.1: Conantokins adopt helical structure in the presence of calcium. NMR
solution structures of ConG that were calculated from data collected in the absence (pdb: 
1AD7, left) and presence (pdb: 1ONU, right) of calcium ions. Structures are shown as 
cartoons representations with gla residues shown as sticks. The inferred positions of calcium 
ions are indicated, even though these are NMR silent.
NMDAR selectivity. For example, ConT is 21 residues yet retains micromolar inhibitory 
activity with C-terminal truncation down to nine residues12. Interestingly, the shortest 
naturally occurring and active conantokin known, conBk-B, is also nine residues in length13.
The first five residues in conantokins are most important, which is indicated by 
mutational scanning experiments that show loss of NMDAR inhibitory activity when any of 
these are substituted with alanine14-16. Also, certain substitutions at residue 5 alter subtype 
selectivity, or cause inactivity in conantokins17,18. However, residue 5 is not the sole 
determinant of selectivity; additional residues contribute to conantokin function19.
The recently discovered conantokin R/-B (conR/-B) from Conus rolani is an ultra- 
selective conantokin that potently inhibits NR2B NMDA receptor subtypes20. The potency
of conRZ-B on NR2B receptor subtypes is similar to that of conG, which was previously the 
most selective conantokin known. However, conRZ-B has a lower potency for NR2A 
containing receptors than does conG, making it a superior pharmacological tool. In addition 
to its selectivity, conR/-B contains a hydroxyproline residue, which is uncommon among 
structurally characterized conantokins. The amino-acid sequences for conRZ-B and other 
representative conantokins are provided in Table 3.1.
In this chapter, the NMR solution structure of conRZ-B is presented. The conRZ-B 
structure is of particular interest because it is the first structure of a hydroxyproline- 
containing conantokin. Through structure comparisons and mutational analyses, the conR/-B 
structure provides insights into determinants of subtype selectivity. ConR/-B was found to 
be a helix-kink-helix, with two short helices interrupted a hydroxyproline residue. This 
structure, taken in context of other work on conantokins, provides insights into mechanisms 
of NMDAR inhibition by conantokins.
Methods
Methods for peptide synthesis and NMR spectroscopy for conRZ-B were similar to 
those described previously for conBk-B13 with the exception that tri-fluoro-ethanol (TFE) 
was not needed to stabilize a helical conformation. A summary of major steps in peptide 
synthesis, data collection, and structure calculation are described below.
Peptide synthesis
The mature peptide sequence for conRZ-B was predicted after analysis of a cDNA 
library from Conus rolani venom glands. ConRZ-B was synthesized using N-(9-fluorenyl) 
methoxycarbonyl (Fmoc) protected amino acids and purified using high-performance liquid 
chromatography (HPLC) on a Vydac C18 semipreparative column. Verification of peptide
38
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Table 3.1: Conantokin sequences
Name Sequence Ref.




ConPr-A GED yYAyGIRyYQLIHGKICooH 24
ConRZ-B GEyy LAy KAOy FARy l a n CONH2 20
mass was performed with electrospray ionization (ESI) mass spectrometry on a Voyager GE 
STR instrument at the University of Utah mass spectrometry core facility.
NM R spectroscopy
HPLC-purified conRZ-B peptide (1000 nmol) was resuspended in NMR buffer to 
yield final concentrations of 1.5 mM peptide, 10 mM MES (13D) pH 6.0, and 15 mM CaCl2. 
One-dimensional proton NMR spectra and two-dimensional NMR spectra including 
heteronuclear single quantum coherence (HSQC), total correlations spectroscopy (TOCSY), 
correlated spectroscopy (COSY), and nuclear Overhauser effect spectroscopy (NOESY) 
spectra were recorded. All data were collected at 20°C on a Varian Inova 600 Mhz 
spectrometer with cryogenic probe. Data were processed with FELIX2004 (Accelrys Inc., 
San Diego, CA) and analyzed using SPARKY (T.D. Goddard and D.G. Kneller, University 
of California, San Francisco). Residue assignments were performed manually through 
examination of HSQC, TOCSY, and NOESY spectra using a sequential residue assignment 
approach. The ensemble of solution structures for conRZ-B was calculated with CYANA (P. 
Guntert, University of Frankfurt, Germany) from 196 inter- and intraresidue NOE distance 
constraints found in the NOESY spectra.
Results 
NM R spectroscopy of conRZ-B 
Analysis of NOESY, TOCSY, COSY, and CHSQC spectra resulted in assignments 
for nuclei of all residues in conRZ-B. The NMR data was of high quality, as evidenced by well 
defined and dispersed resonances. The CHSQC spectrum for conRZ-B is shown in Figure 3.2 
and illustrates the quality of data collected for the conRZ-B peptide. The fingerprint region of 
the NOESY spectrum for conRZ-B and assignments of the amide-proton to alpha-proton 
(NH-HA) resonances are shown in Figure 3.3.
In the NOESY spectra, 196 inter- and intraresidue NOE peaks (NOEs) were 
assigned and subsequently used for structure calculations. The number of NOEs for each 
residue of conRZ-B and the distribution of NOEs by distance are shown in Figure 3.4. 
NOEs were most abundant from residue 5 to 16, with fewer constraints found at the amino- 
and carboxyl- termini. Interestingly, medium range distance constraints were most 
prominent near gla residues (grey bars, Figure 3.4 left panel). This may suggest that the 
helical structure of conantokins is most constrained near calcium-coordinating gla residues.
O f note, NOE constraints were not observed for residues more than four positions 
apart, which is consistent with an a-helix (Figure 3.4 right panel). The Ramachandran plot 
showing phi (^) and psi (^) angle combinations for conRZ-B is presented in Figure 3.5. All 
^ / ^  angle combinations were found to be in optimal regions for an a-helix. Thus, conRZ-B 
is predominantly helical, as has been observed for other conantokin structures.
Consistent with other conantokin structures, conR/-B has significant helical chatacter 
and gla residues are aligned on a single helical face (Figure 3.6). However, the conRZ-B helix 
is interrupted by a hydroxyproline at position 10, resulting in a helix-kink-helix motif that is 
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Figure 3.2: CHSQC spectra from conR/-B. The CHSQC spectrum for conRl-B illustrates 
clear resonance peaks for carbon-hydrogen pairs within the polypeptide. These data were 
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Figure 3.3. NOESY spectra and resonance assignments for conRZ-B. The fingerprint 
region of the NOESY spectra for conRZ-B is depicted with assignments of amide-alpha 












Figure 3.4: Distribution of N O E  constraints for conR/-B. A: NOE constraints by 
residue for conRZ-B structure determination. White bars are intra-residue NOEs (i:i), 
medium-grey are short range (i:i+1-2) and dark-grey are mid-range (i:i+3-4). B: number of 
N OE constrains by range.
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Figure 3.5: Ramachandran diagram for conRZ-B structures calculated in CYANA.















Figure 3.6: The N M R  solution structure of conR/-B. Panel A: The 10-structure 
ensemble of calculated solution structures for conR/-B is shown as lines. Panel B: A single 
representative structure of conR/-B is shown in cartoon representation with hydroxyproline- 
10 and gla residues shown as sticks. This view highlights the helix-kink-helix motif, which is 
a unique feature of conRZ-B.
ensemble, backbone atom positions are consistent and have an average root-mean square 
deviation of (RMSD) of 0.91 ± 0.16 A. The positions of side chain atoms from leu-5 to gla-
11 are also highly consistent. However, amino and carboxyl terminal residue side chains 
exhibit higher conformational variability and the RMSD for all atoms of the peptide is 1.45 ± 
0.17 A.
Discussion
ConR/-B is the most NR2B-selective conantokin known to date, and because of this 
was an important target for structural characterization. Additionally, conR/-B has a 
hydroxyproline residue that is uncommon among structurally characterized conantokins and 
would be expected to alter the standard helical conformation observed in other conantokin 
structures. NMR spectroscopy revealed that conR/-B had significant helical character, similar 
to other conantokins. Consistent with predictions, the helix was interrupted by the 
hydroxyproline residue at position 10. The NMR ensemble of conR/-B revealed a helix-kink- 
helix motif that is unique among structurally characterized conantokins.
The helix-kink-helix of conR/-B differs from straighter helices observed for 
conantokins G and T. A comparison of representative NMR structures for conR/-B, 
ConG11, and ConT11 is shown in Figure 3.7. The kinked conformation of conR/-B suggests 
that a straight a-helix is not the only conantokin conformation that confers NMDAR 
inhibition. Since conR/-B cannot form a straightened helix, yet retains high potency and 
selectivity for NMDARs, the inference can be drawn that receptor-bound conR/-B is not an 
idealized, straight helix. This interpretation suggests that other conantokins may adopt non­
helical conformations upon receptor binding.
Previous structure-function studies on conantokins have shown that amino terminal 





Figure 3.7: Comparison of conRZ-B, conG, and ConT structures. Single representative 
structures are shown from NMR calculated ensembles of conRZ-B, conG (pdb:1ONU), and 
ConT (pdb:1ONT). Most striking is this kinked conformation of conRZ-B compared to the 
straight helices of conG and conT.
conG shows that residues 2-5, 9, and 12 are important determinants of NMDAR inhibitor 
activity14. Similar observations have been made for ConT, where residues 1-5, 8, and 12 are 
important for activity, with residues 2, 4, and 5, particularly important since any change at 
these positions disables NMDAR inhibition12. Among other conantokins, whose structures 
have not yet been determined, amino-terminal residues are also the primary determinants of 
antagonist activity and selectivity15,18,25. These observations suggest that, as with other 
conantokins, the activity and specificity of conRZ-B are defined by amino acids presented on 
the amino terminal half of the kinked helix. Thus, the structural kink itself should not have a 
dominant influence on activity conRZ-B. Consistent with this hypothesis, mutation of 
hydroxyproline to alanine has small effects on both specificity and affinity of conRZ-B for 
NR2B NMDAR subtypes20.
Calcium-dependent, straight helical conformations are consistently observed for 
conantokin peptides. However, conR/-B was found to be a kinked-helix that, even upon 
receptor binding, cannot be forced into a straight helix because of conformational 
constraints imposed by hydroxyproline. If  other conantokins use the same binding 
mechanism as conR/-B, it may be that other conantokins are nonhelical during binding.
Support for the hypothesis that conantokins adopt nonhelical structure during 
receptor binding is found in studies that show calcium ions are not required for inhibition of 
NMDARs, and that conantokins retain inhibitory activity in presence of calcium chelating 
agents12,26,27. These studies suggest that either a helical conformation is not required for 
inhibition of NMDARs or that binding of the NMDAR independently stabilizes the helical 
conformation. Another interesting observation is that conantokin-P, which is active in 
inhibiting NMDARs, contains a long disulfide loop that could make maintenance of a helical 
conformation difficult28. However, it is important to note that the disulfide loop of conP is 
found near the C-terminus, where amino acid identity has less influence on NMDAR 
inhibitory activity. Additionally, conG analogs with engineered covalent "staples" that 
increase peptide helicity, are shown to be less potent than native conG29. So, it appears that 
helicity has small impacts on potency for conantokin peptides and it is likely that a non­
helical conformation is formed upon receptor binding.
Although helicity has little influence on conantokin activity, the highly conserved 
nature of gla residues, which stabilize helical conformation, suggests that gla residues have 
purposeful roles. If  gla residues in conantokins have purpose beyond stabilizing helical 
conformation, the question becomes: What functional role do gla residues have in 
conantokins? In order to hypothesize on this question, it is valuable to examine gla residue 
function in other proteins.
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Gla is a modified form of glutamate that has an additional carboxyl group added 
posttranslationally. The result of this alteration is a nonstandard amino acid that coordinates 
divalent cations such as calcium. Carboxylation of glutamate to form gla is catalyzed by a 
vitamin-K dependent carboxylase and, in mammals, gla-containing proteins are found in 
blood plasma and calcified tissue30. In blood plasma, the gla-rich protein prothrombin is the 
precursor to a protease that is crucial for blood coagulation cascades31. Gla residues in 
prothrombin noncovalently tether the protein to cell membranes via a calcium ion bridge, 
and this interaction is important for activation of thrombin and other surface-dependent 
processes31-34. Perhaps gla residues have evolved to perform similar functions in conantokins.
Presuming that conantokin peptides evolved gla residues to perform functions 
similar to those observed for prothrombin, maybe it is the case that conantokins associate 
with the neuronal membrane prior to or during NMDAR inhibition. Tethering conotoxins 
to the neuronal membrane has potential evolutionary advantages for creating fast-acting and 
highly potent neurotoxins. For example, if conantokins became tethered to neuronal 
membranes, the search time for a receptor could be reduced. Confining the search to the 
surface of a neuron would generate a two-dimensional search from what was previously a 
three-dimensional search, allowing the peptides to act faster. Additionally, tethering would 
decrease the apparent dissociation constants for conantokins, which would help explain 
discrepancies observed between low concentrations of conantokins required to illicit 
behavioral changes and higher concentrations required for inhibition of NMDARs expressed 
in Xenopus ooctypes (Olivera lab, unpublished data). In these cases, differences in membrane 
composition could result in differing affinities for NMDARs. Although there is currently no 
experimental data to support this hypothesis, it could potentially be explored by examining
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conantokin structure in the presence of lipids, or by probing for gla-mediated membrane 
association of conantokins.
In summary, the structure of conRZ-B is unique among structurally characterized 
conantokins. It exhibits a helix-kink-helix motif that differs from other, straighter helices 
observed in previous structure determinations of conantokins. In the conR/-B structure, a 
straight helix is disallowed due to the steric restraints imposed by hydroxyproline at position 
10. Hence, it can be assumed that conRZ-B is not a straight helix when bound to NMDARs. 
This idea hints that other conantokins might not retain helicity during receptor binding, and 
that gla residues may have function beyond stabilizing helical structure. Consequently, 
alternative roles for gla residues in conantokins should be explored. Additionally, although 
the kinked conformation of conRZ-B is striking, it is unlikely that the kink governs high 
specificity for NR2B receptors. A more reasonable hypothesis is that the amino-acid 
combination in the first 10 residues leads to subtype selectivity. Therefore, systematic alanine 
scanning and designed substitutions would be useful for understanding determinants of 
specificity in conRZ-B. The results presented here and elsewhere indicate that no single 
residue determines subtype selectivity in conantokins. Rather, it is multiple residues, and the 





1 Haack, J. A. et aZ. Conantokin-T. A gamma-carboxyglutamate containing peptide with 
N-methyl-D-aspartate antagonist activity. The JournaZ of BioZogicaZ Chemistry 265, 6025­
6029 (1990).
2 Mena, E. E. et aZ. Conantokin-G: a novel peptide antagonist to the N-methyl-D- 
aspartic acid (NMDA) receptor. Neuroscience Letters 118, 241-244 (1990).
3 Hammerland, L. Conantokin-G selectively inhibits N-methyl-D-aspartate-induced 
currents in Xenopus oocytes injected with mouse brain mRNA. European JournaZ of 
PharmacoZogy: MoZecuZar Pharmacology 226, 239-244 (1992).
4 Prorok, M., Warder, S. E., Blandl, T. & Castellino, F. J. Calcium binding properties 
of synthetic gamma-carboxyglutamic acid-containing marine cone snail "sleeper" 
peptides, conantokin-G and conantokin-T. Biochemistry 35, 16528-16534 (1996).
5 Lin, C. H., Chen, C. S., Hsu, K. S., King, D. S. & Lyu, P. C. Role of modified 
glutamic acid in the helical structure of conantokin-T. Federation of European 
BiochemicaZSciences Letters 407, 243-248 (1997).
6 Rigby, A. C. et aZ. Role of gamma-carboxyglutamic acid in the calcium-induced 
structural transition of conantokin G, a conotoxin from the marine snail Conus 
geographus. Biochemistry 36, 15677-15684 (1997).
7 Warder, S. E. et aZ. The NMR solution structure of the NMDA receptor antagonist, 
conantokin-T, in the absence of divalent metal ions. Federation of European BiochemicaZ 
Sciences Letters 411, 19-26 (1997).
8 Warder, S. E. et aZ. The roles of individual gamma-carboxyglutamate residues in the 
solution structure and cation-dependent properties of conantokin-T. The JournaZ of 
BioZogicaZ Chemistry 273, 7512-7522 (1998).
9 Blandl, T., Warder, S. E., Prorok, M. & Castellino, F. J. Binding of cations to 
individual gamma-carboxyglutamate residues of conantokin-G and conantokin-T.
The JournaZ of Peptide Research 53, 453-464 (1999).
10 Rigby, A. C., Baleja, J. D., Furie, B. C. & Furie, B. Three-dimensional structure of a 
gamma-carboxyglutamic acid-containing conotoxin, conantokin G, from the marine 
snail Conus geographus: the metal-free conformer. Biochemistry 36, 6906-6914 (1997).
11 Skjaerbaek, N., Nielsen, K. J., Lewis, R. J., Alewood, P. & Craik, D. J. Determination 
of the solution structures of conantokin-G and conantokin-T by CD and NMR 
spectroscopy. The JournaZof BioZogicaZ Chemistry 272, 2291-2299 (1997).
12 Warder, S. E., Blandl, T., Klein, R. C., Castellino, F. J. & Prorok, M. Amino acid 
determinants for NMDA receptor inhibition by conantokin-T. JournaZ of 















Platt, R. J. et al. From molecular phylogeny towards differentiating pharmacology for 
NMDA receptor subtypes. Toxicon 81, 67-79 (2014).
Blandl, T., Prorok, M. & Castellino, F. J. NMDA-receptor antagonist requirements in 
conantokin-G. Federation of European Biochemical Sciences Letters 435, 257-262 (1998).
Blandl, T., Zajicek, J. & Prorok, M. Sequence requirements for the N-Methyl-D- 
aspartate receptor antagonist activity of conantokin-R. Journal of Biological Chemistry 
276, 7391-7396 (2001).
Prorok, M. & Castellino, F. The molecular basis of conantokin antagonism of 
NMDA receptor function. Current Drug Targets 8, 633-642 (2007).
Klein, R. C., Prorok, M., Galdzicki, Z. & Castellino, F. J. The amino acid residue at 
sequence position 5 in the conantokin peptides partially governs subunit-selective 
antagonism of recombinant N-methyl-D-aspartate receptors. The Journal of Biological 
Chemistry 276, 26860-26867 (2001).
Twede, V. D. et al.Conantokin-Br from Conus brettinghami and selectivity 
determinants for the NR2D subunit of the NMDA receptor. Biochemistry 48, 4063­
4073 (2009).
Sheng, Z., Prorok, M. & Castellino, F. J. Specific determinants of conantokins that 
dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.
Neuroscience 170, 703-710 (2010).
Gowd, K. H. et al. Conantokins derived from the Asprella clade impart conRl-B, an 
N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B 
subunits. Biochemistry 51, 4685-4692 (2012).
Rivier, J. et al.Total synthesis and further characterization of the gamma- 
carboxyglutamate-containing "sleeper" peptide from Conus geographus venom. 
Biochemistry 26, 8508-8512 (1987).
White, H. S. et al. In vitro and in vivo characterization of conantokin-R, a selective 
NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus 
radiatus. The Journal of Pharmacology and Experimental Therapeutics 292, 425-432 (2000).
Jimenez, E. C. et al. Conantokin-L, a new NMDA receptor antagonist: determinants 
for anticonvulsant potency. Epilepsy Research 51, 73-80 (2002).
Teichert, R. W. et al. Novel conantokins from Conus parius venom are specific 
antagonists of N-methyl-D-aspartate receptors. The Journal of Biological Chemistry 282, 
36905-36913 (2007).
Blandl, T., Warder, S. E., Prorok, M. & Castellino, F. J. Structure-function 
relationships of the NMDA receptor antagonist peptide, conantokin-R. Federation of 
European Biochemical Sciences Letters 470, 139-146 (2000).
52
26 Klein, R. C. & Castellino, F. J. Inhibition of MK801 binding in adult rat brain 
sections by conantokin-G and conantokin-T. Neuroscience Letters 273, 171-174 (1999).
27 Klein, R. C., Prorok, M. & Castellino, F. J. Direct binding properties of conantokins 
to native N-methyl-D-aspartate receptors. The Journal of Peptide Research 61, 307-317 
(2003).
28 Gowd, K. H. et al. Conantokin-P, an unusual conantokin with a long disulfide loop. 
Toxcon 52, 203-213 (2008).
29 Platt, R. J. et aZ. Stapling mimics noncovalent interactions of gamma- 
carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid 
receptors. Journal of Biological Chemistry 287, 20727-20736 (2012).
30 Vermeer, C. Gamma-carboxyglutamate-containing proteins and the vitamin In­
dependent carboxylase. Biochemical Journal 266, 625-636 (1990).
31 Bradford, H. N., Orcutt, S. J. & Krishnaswamy, S. Membrane binding by 
prothrombin mediates its constrained presentation to prothrombinase for cleavage. 
Journal of Biological Chemistry 288, 27789-27800 (2013).
32 Gitel, S. N., Owen, W. G., Esmon, C. T. & Jackson, C. M. A polypeptide region of 
bovine prothrombin specific for binding to phospholipids. Proceedings of the National 
Academy of Sciences 70, 1344-1348 (1973).
33 Mann, K. G., Nesheim, M. E., Church, W. R., Haley, P. & Krishnaswamy, S. 
Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 
76, 1-16 (1990).
34 Nelsestuen, G. L. Role of gamma-carboxyglutamic acid. An unusual protein 
transition required for the calcium-dependent binding of prothrombin to 
phospholipid. Journal of Biological Chemistry 251, 5648-5656 (1976).
CHAPTER 4
HETEROLOGOUS EXPRESSION OF NMDA RECEPTOR LIGAND-BINDING
DOMAINS IN ESCHERICHIA COLI
Preface
In order to define rules that govern subtype selective inhibition of N-methyl-D- 
aspartate receptors (NMDARs) by conantokin peptides, it would be useful to obtain a 
detailed molecular picture of the binding interface. The structure of a conantokin-NMDAR 
complex would elucidate mechanisms of inhibition, details of subtype selectivity, and 
promote development of increasingly selective conantokins. To this end, the following 
chapter outlines the cloning, expression, purification, and biochemical analysis of NMDAR 
ligand binding domains (LBDs). Unfortunately, the final experiments did not show direct 
interactions between LBDs and conantokins. Nonetheless, the LBD proteins produced may 
become useful tools for screening other NMDAR antagonists, and the negative results 
provided insights into mechanisms of conantokin-NMDAR binding. Furthermore, the 
results presented were inconclusive, and it may prove to be the case that conantokins indeed 
interact with the LBD albeit only weakly or only in the presence of additional protein 
domains and protein subunits yet to be discovered.
Introduction
To date it is unclear how and where conantokins bind NMDARs and conflicting 
evidence exists to support two binding mechanisms. Some studies indicate conantokins
compete with agonists at the glutamate-binding site on NR2 subunits of the NMDAR. 
Others suggest a noncompetitive interaction near the polyamine-binding site on the amino- 
terminal domain (ATD) of NR2 subunits. The details of these studies are described below.
Evidence for a noncompetitive mechanism of conantokin binding 
Most evidence that conantokins bind noncompetitively to the ATD comes from 
studies performed on brain slices or cultured neuron preparations. For example, conG 
inhibition of N-methyl-D-aspartate (NMDA) stimulated responses in cultured neurons and 
brain slices show that conG inhibition was not overcome with saturating NMDA1. Also, in 
[3H]MK-801 binding assays on rat forebrains, conG reduced spermine- and spermidine- 
stimulated radioligand binding but did not alter glutamate-stimulated radioligand binding2. 
Interestingly, conG analogs with tyrosine or glutamate added to the amino-terminus were 
observed to have polyamine-like effects that enhance [3H]MK-801 binding3. Taken together, 
these studies suggest conantokins are noncompetitive NMDAR antagonists that bind to a 
site on the ATD that is distant and disctinct from the agonist-binding site located on the 
LBD.
Evidence for a competitive mechanism of conantokin binding 
Contrasting evidence for a competitive mechanism of conantokins binding to the 
LBD comes from multiple sources. In Xenopus oocytes expressing NMDARs, conG 
inhibition of NMDA elicited current were overcome with saturating NMDA4. Additionally, 
the pre-application of conG shifts excitatory dose-response curves for glutamate, indicative 
of a competitive mechanism of interaction4. In other experimental systems, ConG inhibition 
of NMDA-stimulated responses in mouse cortical neurons were prevented by pre­
application of NMDA5. Also, direct-binding studies show that NMDA and 2-amino-5-
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phosphoonopentanoic acid (AP5), a known competitive antagonist of NMDARs, prevented 
binding of radiolabelled conG6. Moreover, point mutations at or near the glutamate-binding 
site in NMDARs were shown to alter conG potency7,8. As a whole, these studies suggest that 
conantokins are competitive NMDAR antagonists that bind to the LBD. However, when 
considering all of the research together, it appears that conantokins have a complex 
mechanism of NMDAR inhibition that may be mediated through interactions with both the 
LBD and the ATD.
Contents of Chapter 4 
In order to examine if conantokins bind to the NMDAR LBD, I sought to create a 
soluble form of the LBD domain that could be studied biochemically. Full-length NMDAR 
clones from rat cDNA were used to generate gene constructs encoding the LBD portion of 
the NMDAR for NR1-2b, NR2A, NR2B, and NR2D subunits. The boundaries used to 
delineate NMDAR LBD domains for expression in bacteria were modeled from previous 
work that led to successful crystallization of LBDs from NR1 and NR2A, as well as an NR1- 
NR2A heterodimer9,10. In NMDARs two primary sequence regions, termed S1 and S2, fold 
together to create the ligand-binding clamshell. LBD domains described here were created 
by connecting S1 and S2 regions of the NMDAR with a glycine-threonine (GT) linker. The 
resulting proteins were expressed in bacteria, purified, and shown to bind cognate ligands. 
Alas, assays for conantokin-LBD binding showed no interaction. Taken in the context of 




Cloning NM DAR LBDs from rat cDNA 
Clones of the NR1, NR2A, NR2B, and NR2D NMDAR subtypes from Rattus 
norvegicus cDNA libraries were used to generate LBD-encoding genes by applying polymerase 
incomplete primer extension (PIPE) techniques11. Boundaries for the LBD domain were 
modeled after previous work for the NR1 and NR2A subunits10. Sequence alignment with 
NR2A determined boundaries for the NR2B and NR2D subunits. DNA encoding the 
NMDAR LBD was placed downstream of a 8xHIS tag and inserted into a pET22b+ vector 
from Novagen. DNA sequences were verified through the University of Utah Health 
Sciences Center sequence core. Plasmid DNA was produced in DH5a bacterial cells and 
isolated with a plasmid purification kit (Qiagen). Plasmid DNAs were transformed using 
heat-shock into Origami B (Novagen) E . coli host strain for heterologous protein expression.
Protein expression and cell lysis 
Origami B cells (Novagen) harboring NMDAR LBD encoding plasmids were grown 
in standard 2XYT media supplemented with 40 mM KPO4, 5 mM glucose, 500 ^g/mL 
amplicillin, 10^g/mL kanamycin, and 12.5 ^g/mL tetracycline. Bacterial cultures were 
started in 2 mL media from frozen stocks and grown overnight at 37°C. Cells from 
overnight starter cultures were harvested with centrifugation and washed before inoculating 
60 mL of fresh media. When the optical density at 600 nm (OD600) achieved a value of 0.8­
1.0, bacteria from 60 mL cultures were harvested with centrifugation, washed two times with 
media, and used to inoculate 1 L of fresh media. One-liter cultures were grown at 37°C to an 
OD600 of 0.7-1.0 and then induced by cooling culture flasks in an ice bath for 5 minutes, 
and adding the chemical inducing agent isopropyl P-D-1-thiogalactopyanoside (IPTG).
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Induced cultures were moved to a refrigerated shaking incubator maintained at 19- 
20°C for the protein expression phase over a period of 24-60 hours. The optimal 
temperature and time for protein expression was independently determined for each 
NMDAR subtype (see Results section). Cells were harvested with centrifugation and the 
resulting cell pellet was frozen at -20°C. For protein extraction, frozen cell pellets were 
thawed in ice-cold lysis buffer and cell lysis was performed with a combination of lysozyme 
treatment and sonication in lysis buffers that were optimized for each NMDAR subtype (see 
Results section). Insoluble portions of the bacterial lysate were removed with centrifugation 
and filtration. The soluble fraction was utilized for purification of NMDAR LBD proteins.
Protein purification
Clarified cell lysates containing soluble proteins were incubated with 1 mL of packed 
nickel-nitrilotriacetic acid (Ni-NTA) His-binding resin per 2 L of culture in batch-mode for 
1-4 hours at 4°C. The resin was washed with wash buffer containing 0.1 M HEPES pH 7, 
0.25 M NaCl, 50 mM glutamate, 5 mM glycine, and 25 mM imidazole and protein was eluted 
in elution buffer of the same composition but containing 250 mM imidazole.
Ni-NTA eluted proteins went through two stages of additional purification using 
fast-protein-liquid-chromatography (FPLC) on an AKTA FPLC system (GE life sciences). 
Size exclusion chromatography (SEC) was performed on a Superdex-75 gel filtration column 
and SEC buffers were optimized independently for each NMDAR LBD subtype (see Results 
section). Depending on the calculated iso-electric point for each protein subtype, cation or 
anion exchange chromatography were used as the final purification step. Ion exchange 
buffers were optimized independently for each protein subtype (see Results section). Protein 
was monitored through various stages of purification using sodium dodecyl sulfate
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polyacrylamide gel electrophoresis (SDS-PAGE), following protocols adapted after Schagger 
and Von Jagow12. Protein bands were visualized by staining with coomassie blue or silver.
Results 
Cloning of NM DAR LBDs 
Genes encoding NMDAR LBDs were successfully integrated into pET-22b(+) 
vectors for the NR1-2b, NR2A, NR2B, and NR2D NMDAR subtypes. Figure 4.1 illustrates 
the approach for creating NMDAR LBDs from full length NMDARs. Linking two stretches 
of amino acid residues, termed S1 and S2 in the full-length NMDAR, created the LBD 
domains that were ultimately expressed in bacteria. DNAs encoding the S1 and S2 regions 
were cloned out of full-length NMDAR genes from rat, and S1 was connected to S2 with a 
two amino-acid glycine-threonine (GT). The LBD was placed downstream of a 8xHIS tag 
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Figure 4.1: Cloning NM DAR LBDs A: LBD boundaries mapped onto the crystal 
structure of NR2B (pdb:4PE5). The LBD is highlighted in black. B: A DNA sequencing 
read from NR2B verifies proper cloning of LBDs. C: Domain organization of a NMDAR. 
D: Subdomain organization of a NMDAR LBD.
Bacterial host strains for protein expression 
Two bacterial host strains were transformed with the PET-22b(+) vector containing 
DNA encoding NMDAR LBDs, and these were tested for protein expression. As shown by 
SDS-PAGE of total protein, the Rosetta (Novagen) failed to express LBD protein and the 
OrigamiB (Novagen) cell strain expressed LBD protein at high levels. Therefore the 
OrigamiB host strain was used in subsequent experiments to optimize protein expression.
NM DAR LBDs express as insoluble protein 
Typical protein expression conditions, with bacterial growth temperatures from 20­
37 °C and induction with 0.5-1 mM IPTG, resulted in high protein yield, but little or none of 
this protein was soluble. Figure 4.2 illustrates representative results obtained for these initial 
NR2D-LBD expression tests. Similar results were obtained for all NMDAR LBD subtypes 
tested.
The preponderance of insoluble protein, expressed under standard culture 
conditions, led to two independent approaches for generating folded and functional 
NMDAR LBD proteins. One approach was to denature, purify, and refold the insoluble 
proteins; a second approach was to optimize culture conditions to encourage expression of 
soluble protein.
I estimated a yield of >30mg insoluble protein per liter of culture. Denaturation and 
purification of denatured protein led to large yields of highly pure protein. However, 
refolding resulted in significant loss via protein precipitation (data not shown). Ultimately, 
optimization of culture conditions, selecting for those conditions that favored expression of 



























Figure 4.2: NMDAR LBDs express as insoluble proteins. A: SDS-PAGE analysis of 
soluble protein yield for the NR2D LBD induced with 0.5 mM IPTG for 24 hours at 20 °C. 
B: Insoluble protein yield from the same culture. NMDAR LBDs express strongly and are 
found in the insoluble portion of bacterial lysates.
Assay development
Soluble protein yield was not evident in SDS-PAGE analysis of crude bacterial 
lysates; meaning improvements in the expression of soluble protein would not be detectable 
with the standard assay. To overcome this, I developed a nickel-nitrilotriacetic acid (Ni- 
NTA) pull-down assay to analyze soluble protein yield. In the pull-down assay, crude 
bacterial extracts were clarified by centrifugation and the clarified extract was combined with 
Ni-NTA his-binding resin to capture soluble LBD proteins. To detect captured soluble 
protein, Ni-NTA resin was collected by centrifugation, washed in buffer, and suspended 
directly in SDS loading buffer for analysis by SDS-PAGE. Under these conditions, the very 
low levels of soluble NMDAR LBD proteins were enriched, allowing for detection and
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comparison of soluble LBD protein yield as a function of different culture conditions.
Optimizing soluble protein yield 
Testing the variables of temperature and IPTG concentration showed that lowering 
the temperature and reducing the IPTG concentration increased soluble protein yield. 
Reducing the IPTG concentration had the opposite effect on total protein yield, which 
decreased, implying that lower overall protein expression encourages the soluble form to 
accumulate. An IPTG concentration of 5^M with an expression temperature of 20°C 
provided the highest yields of soluble LBD proteins (Figure 4.3). Similar results were 
obtained for LBD proteins from each of the NR1, NR2A, NR2B, and NR2D subunits.
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Figure 4.3 Low IPTG concentrations yield more soluble LBD protein. SDS-PAGE 
analysis of the NR2B LBD expressed at 20°C for 30 hours with different IPTG 
concentrations. Total protein yield increased with increasing IPTG concentration. However, 
yield of Ni-NTA captured protein (soluble) was optimal at 5^M IPTG (black arrow). IPTG 
concentrations above 5 ^M resulted in decreased or undetectable yields of soluble protein.
In addition to induction temperature and IPTG concentration, additional variables 
were optimized, including the O D 6OO at induction, the duration of expression, and the 
composition of the lysis buffer (pH, ionic strength, additives). Figure 4.4 shows results 
obtained for the NMDAR NR2B LBD protein while optimizing O D 6OO at induction, 
duration of expression, and lysis buffer composition. For the NR2B LBD, an OD  of 0.9 at 
induction, 30 hours expression time, and the TEB5 lysis buffer containing 0.1 M Tris pH 
8.2, 50 mM glutamate, and 50 mM glycine were optimal for producing soluble protein.
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Figure 4.4: Optimization of induction timing, expression time, and lysis buffers.
SDS-PAGE analyses of soluble protein yield during optimization of culture conditions for 
the NR2B LBD protein. The best conditions are marked with stars and arrows indicate 
position of the protein band corresponding to the NR2B LBD protein. A: Optimization of 
optical density at induction. B: Optimization of expression time. C: Optimization of lysis 
buffer.
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Cell lysis, protein capture, and purification of NM DAR LBDs 
Following optimization of protein expression and Ni-NTA capture, further 
purification of the captured proteins was necessary. NMDAR LBD proteins were eluted 
from Ni-NTA resin using high imidazole concentrations and purified with a combination of 
size exclusion and ion exchange chromatography. Optimization of buffers and purification 
conditions for each of the purification steps was necessary to prevent protein precipitation 
and product loss. Figure 4.5 shows chromatograms from SEC and ion-exchange purification 
of the NR2B LBD protein after optimization of protein purification conditions.
After the three-stage purification, highly purified proteins were obtained for all four 
NMDAR LBD protein subunits tested. The optimized conditions for protein expression and 
purification of each NMDAR LBD subtype are provided in Table 4.1, along with yields per 
liter of culture. Other parameters, not shown in Table 4.1, were found to be similar for all 
NMDAR LBD subtypes; these included expression temperature (19-20 °C optimal), OD  at 
induction (0.7 - 1 optimal), and IPTG concentration (0-5 ^M optimal).
Figure 4.5: FPLC Purification of N M DAR LBD proteins. The results of size exclusion 
and ion exchange chromatography for the NR2B LBD protein are shown. Arrows indicate 
absorbance peaks corresponding to the LBD protein. The grey line on the right panel shows 
changes in buffer conductivity while eluting with a salt gradient from 50mM to 1M NaCl. 
After ion-exchange chromatography, the NMDAR LBD proteins are highly purified.
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0.1 M Tris pH 8.2 
50 mM glutamate 
50 mM glycine 
0.5% w /v CHAPS 
1 mM PMSF 
50 [Ag/ml, lysozyme
25 mM MES pH 6.5 
250 mM NaCl 
10 mM glycine
Cation Exchange
25 mM MES pH 6.5 




0.1 M Tris pH 8.2 
50 mM glutamate 
50 mM glycine 
0.5% w /v CHAPS 
1 mM PMSF 
50 [Ag/ml, lysozyme
25 mM MES pH 6.5 
150 mM NaCl 
10 mM glutamate
Cation Exchange
25 mM MES pH 6.5 




0.1 M Tris pH 8.2 
50 mM glutamate 
50 mM glycine 
0.5% w /v CHAPS 
1 mM PMSF 
50 [Ag/ml, lysozyme








0.1 M Tris pH 8.2 
50 mM glutamate 
50 mM glycine 
0.5% w /v CHAPS 
1 mM PMSF 
50 [Ag/ml, lysozyme
25 mM Tris pH 8.5 
50 mM NaCl 
10 mM glutamate
* Anion Exchange* 
25 mM Tris pH 8.0 
100 mm NaCl 
*Isocratic elution at 
lOOmM NaCl*
0.4-0.6 mg
Limited proteolysis of NM DAR LBD proteins
Limited proteolysis is a technique used to examine stability of soluble proteins and 
protein domains, and changes in proteolysis profiles can reflect conformational changes 
associated with protein-protein or protein-ligand interactions13-15. The technique incorporates 
protease enzymes, which break peptide bonds and digest proteins into smaller pieces. 
Proteolysis profiles reveal stable protein domains, which are seen as protease-resistant 
protein bands in SDS-PAGE analysis. To examine the stability of purified NMDAR LBD 
proteins, and to test for the possibility of ligand-LBD interactions, LBD proteins went 
through limited proteolysis experiments under various conditions with and without potential 
ligands.
At first, NMDAR LBD proteins were treated with either trypsin or chymotrypsin 
and the products of these reactions were analyzed by SDS-PAGE. Figure 4.6 shows the 
proteolysis profile obtained for the NR2B LBD following a 60-minute digest at 25 °C with 
varied amounts of the proteases trypsin and chymotrypsin. In the proteolysis profiles, some 
reaction products accumulated more than others, which can be seen as darker protein bands 
in the gel image. Accumulating proteolysis products suggested that the NR2B LBD had 
stable domains that were resistant to proteolysis. Also, the observation that the NR2B LBD 
resisted complete degradation, at least at lower enzyme concentrations, suggested that the 
protein had adopted a stable tertiary structure. Altogether, results indicated that the LBD 
protein had a stable fold and that limited proteolysis could be applied to test for ligand 
binding.
After determining that LBD proteins were adopting stable folds, limited proteolysis 
assays were further used to examine binding of ligands to NMDAR LBDs. First, the NR2B 
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Figure 4.6: Limited proteolysis profiles for the LBD reveal stable, folded protein.
SDS-PAGE analysis of proteolysis reaction products from the NR2B LBD protein after 
incubation with chymotrypsin or trypsin for 60 minutes at 25 °C. Mass ratio indicates the 
ratio of protease to LBD measured by mass. For smaller mass ratios, the NR2B LBD was 
resistant to proteolysis, indicating stable tertiary structure. Accumulation of particular 
proteolysis products indicates the presence of stable domains within the LBD. The level of 
the protein band corresponding to full-length NR2B LBD is specified with an arrowhead.
limited proteolysis. The binding constant for glutamate on NMDA receptor tetramers is ~1 
^M; 100^M glutamate was used to achieve saturation in the assay. The results are presented 
in Figure 4.7, which shows that glutamate had a strong protective effect on NR2B; glutamate 
slowed the proteolysis of the NR2B LBD by chymotrypsin. The protective effect of 
glutamate was not seen for a control protein (p56a), which was not expected to interact with 
glutamate. Contrasting effects of glutamate on the NR2B LBD and on p56a indicates that 
protection from proteolysis by glutamate was mediated through interaction of glutamate 
with the LBD and not through inhibition of the protease by glutamate. These results suggest 
that the NR2B LBD protein binds to glutamate and is likely to have a structure similar to the 
glutamate-binding LBD domain of a complete NMDAR.
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Figure 4.7: Glutamate protects the NR2B LBD from proteolysis with chymotrypsin.
SDS-PAGE analysis of proteolysis reaction products over time, with experiments performed 
in the presence or absence of glutamate. The full length NR2B LBD (left arrow) was 
completely degraded after 60-minute exposure to chymotrypsin at 30 °C with a mass ratio of 
1:50. In the presence of 100 ^M glutamate, proteolysis of the LBD by chymotrypsin was 
significantly slowed and the full length LBD protein remained detectable after 60 minutes. In 
contrast, the control protein p56a (right arrow) was not protected by glutamate. These 
results show that the NR2B LBD protein interacts with glutamate.
Because glutamate exerted a protective effect on the NR2B LBD protein in 
proteolysis assays, additional experiments were performed utilizing the agonists NMDA and 
glycine, as well as the antagonists (2R)-amino-5-phsphonovaleric acid (AP-5), conantokin Rl- 
B, and conantokin Rl-E[V10O]. Interestingly, the NMDAR antagonist AP-5 had protective 
effects similar to those observed for glutamate and NMDA (Figure 4.8). This result would 
be expected, however, because any molecule that stabilizes the conformation of the LBD 
should limit access to protease cleavage sites and slow the rate of proteolysis. Furthermore, 
AP5 is known to bind to the same site as glutamate and would therefore be expected to have 
similar effects in proteolysis assays. In contrast to the small molecule agonists and 
antagonists that were tested, conantokin peptides failed to protect LBD proteins from 
proteolysis (data not shown). The results with conantokins could mean that conantokins do
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Figure 4.8: Protection from proteolysis by LBD-binding agonists and antagonists.
Proteolysis reaction products analyzed by SDS-PAGE show that the NR2B LBD protein 
was protected against proteolysis in a concentration-dependent manner for the agonists 
glutamate and NMDA, and for the antagonist AP-5. These proteolysis reactions were 
performed with a mass ratio of 1:50 with incubation at 30 °C for 120 minutes. The arrow 
indicates the position of the full length LBD protein.
not bind to the NR2B LBD protein, that conantokin-LBD interactions were transient and 
not detected by proteolysis, or that the conantokin peptides were degraded by protease 
during the assay.
In NMDAR tetramers, NR1 subunits bind glycine and NR2 subunits bind glutamate. 
Together, the co-agonists glycine and glutamate act to open the ion channel pore. Because of 
this, I hypothesized that the NR1-LBD would be protected by glycine but not by glutamate 
or NMDA. Figure 4.9 compares proteolysis profiles obtained for NR1, NR2A, NR2B, and 
NR2D LBDs in the presence and absence of glycine, glutamate, and NMDA. Consistent 
with expectations, glycine protected the NR1 LBD protein but did not protect the NR2- 
LBD proteins. Also consistent with agonist-specificity, glutamate and NMDA protected all 
NR2-LBD proteins but not the NR1 LBD protein. Intriguingly, the degree of ligand- 
mediated protection for the NR2D LBD was weak by comparison with protection observed 
for NR2A and NR2B LBD proteins. Weaker protection may reflect weaker interaction of 
ligand with the NR2D LBD, or it may indicate that a portion of the NR2D LBD was 
improperly folded.
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Figure 4.9: Agonist protection of NR1, NR2A, NR2B, and NR2D LBD proteins.
Proteolysis products observed with SDS-PAGE after trypsin digestions in the presence and 
absence of various ligands. A mass ratio of 1:50 was used with a digestion time of 60 
minutes at 30 °C. The assay tested protective effects of the ligands glycine, glutamate, and 
NMDA. Glycine protected the NR1 LBD protein, while glutamate and NMDA protected 
NR2 LBD proteins. These results are consistent with expectations for cognate agonists of 
the NR1 and NR2 subunits of the NMDAR.
Probing conantokin-NMDAR binding with SEC
Conantokin to LBD interactions were also examined by comparing elution times in 
SEC chromatograms. Elution times in SEC are dependent on the shape and size of protein 
molecules. In SEC, these features are described as the radius of gyration, which can be 
changed by binding to other molecules. Since the NMDAR LBD proteins range from 33.3 - 
35.0 kDa and conR-B is 2.2 kDa, the expected size difference between the LBD and a 
conantokin-bound LBD (~6%) was potentially observable with SEC. However, in addition 
to changes in radius of gyration, the off-rate of binding must be slow to observe effects with 
SEC. Fortunately, conR-B is known to have slow off-rate kinetics in electrophysiology 
experiments examining NMDAR tetramers associated with the cell membrane (Olivera Lab, 
personal communication), and was therefore used to examine conantokin-LBD binding with 
SEC.
Unfortunately, elution-times were identical for the NR2B LBD protein with and 
without saturating conR l-B (data not shown). These results could indicate that the LBD
protein domain is insufficient for productive toxin binding or that the uncomplexed LBD 
and the toxin-LBD complex have highly similar radii of gyration that have identical elution 
times when analyzed with SEC. To address the concern that complexed and uncomplexed 
LBD proteins have imperceptibly different radii of gyration, I repeated the experiment, this 
time examining elution times for conR/-B[L5Y] in the presence and absence of LBD 
proteins. ConR/-B[L5Y] retains similar NMDAR inhibitory activity to native conR/-B16, but is 
visible with absorbance at 280nm and is therefore directly detected in SEC elution profiles. 
Disappointingly, no difference was observed for elution time of conR/-B[L5Y] in the 
presence and absence of the NR2B LBD protein (Figure 4.10). Therefore, the NR2B LBD is 
insufficient for productive toxin binding, or the complexed state is not stable enough to 




Figure 4.10: SEC chromatography shows no binding of conantokins to LBD proteins.
Superdex75 SEC chromatographs for LBD, conantokin, and LBD+conantokin (1:1 molar 
ratio). No differences in retention time were observed for either conantokin or LBD protein, 
indicated with arrows, suggesting that the proteins did not interact.
Summary
Genes encoding the LBD from four different NMDAR subunits were cloned into 
pET-22a expression vectors, transformed into OrigamiB (Novagen) host strains, expressed 
as soluble proteins, purified with liquid chromatography, and tested for molecular interaction 
with ligands using a proteolysis assay and by SEC. Optimizations of protein expression and 
purification conditions for each NMDAR subtype resulted in yields of 0.6-2.8 mg per 3 L of 
culture. In proteolysis assays, soluble NMDAR-LBD proteins were protected by cognate 
ligands, which suggests that the NMDAR LBD proteins adopt a structure that is 
biochemically active and similar to the structure of this domain as found in the context of 
the assembled NMDAR tetramer. Changes in the proteolysis profile indicated a molecular 
response to known agonists and antagonists; however, this was not the case in tests with 
conantokins. The NR2B LBD tested was not protected by conantokin in the proteolysis 
assay, and neither LBD nor conantokin appeared to change behavior in SEC experiments. 
Although there are alternative explanations for these negative results, the simplest 
explanation is that molecular interaction between isolated LBD protein and conantokin is 
weak or nonexistent.
Discussion 
Protein expression and purification 
The NMDAR LBD constructs described here were modeled after those previously 
used for crystallization of NMDAR LBD monomers and heterodimers9,10. Those NMDA- 
LBD constructs were also modeled from earlier work on AMPA type glutamate 
receptors17,18. Compared to previously reported results, my yield per liter of culture for 
NMDAR LBD proteins was low with less than 1 mg/L culture. For well-behaved soluble 
proteins, a yield greater than 10 mg/L culture is often expected. With the LBD yields
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obtained here, and the protein concentrations necessary for crystallization, a very large-scale 
expression approach would be necessary. Such approaches are both costly and time 
consuming. Therefore, alternative methods of heterologous protein expression may be 
desirable for creating complicated mammalian proteins.
Beyond bacteria, insect cells are another platform for heterologous expression of 
proteins that may be useful for expression of proteins from eukaryotes. Interestingly, the 
initial characterization of NR1 S1S2 constructs used proteins expressed from insect cell 
derived expression systems19,20. Presumably, one would desire to express a eukaryotic protein 
in a eukaryotic host. Eukaryotic hosts potentially express chaperone proteins and cofactors 
that help with expression and folding of proteins. Although insect cell expression systems 
have their own technical challenges, they are gaining popularity for the expression of 
complex eukaryotic proteins and multiprotein complexes21-23. Noteworthy is the observation 
that insect cell expression systems were used for structure determination of the tetrameric 
NR12/NR2B2 NMDAR containing the ATD, LBD, and partial transmembrane helices 
published earlier this year24. Results from many current studies indicate that when 
recombinant proteins from eukaryotic organisms are desired, it may be of benefit to explore 
expression systems derived from eukaryotes as opposed to prokaryotes.
Limited proteolysis of NM DAR LBDs 
Proteolysis assays performed on the NMDAR LBD proteins for NR1-2b, NR2A, 
NR2B, and NR2D provided evidence that soluble, purified LBD proteins were correctly 
folded. These proteins were not found to bind conantokin peptides, but they can now be 
utilized to screen novel agonists or antagonists that interact with the LBD of the NMDAR.
The negative results for conantokin binding in proteolysis assays are nonetheless 
revealing and should not be regarded as failures. Some research has indicated that
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conantokins are competitive antagonists binding at the LBD5,7,8 and other research has 
suggested conantokins are noncompetitive antagonists that bind the ATD2,3. The results 
presented here illuminate that LBD monomers are not sufficient for conantokin binding, yet 
previous studies illustrate the LBD is important for conantokin binding.
Taken in the context of previous studies, our results indicate that conantokins likely 
require the LBD and additional protein domains or subunits for tight binding. Because 
previous studies indicate the ATD is a site of conantokin interaction, it would be beneficial 
to examine conantokin interactions with ATD-LBD protein constructs. Accordingly, 
optimization of NMDAR ATD-LBD protein expression and purification is an ongoing 
project in the Horvath laboratory. Although the ATD is most likely the missing piece for 
conantokin-NMDAR interactions, other hypotheses should not be neglected.
Some studies have noted that NR1 splice variation can influence conantokin 
efficacy5,7. This indicates that the conantokin-binding site may be created at the interface 
between NR1 and NR2 subunits, as these assemble to form the complete NMDAR 
tetramer. Fortunately, the recent publication of a tetrameric NMDAR crystal structure24 
makes this hypothesis testable. Difference maps calculated by comparing structure factors 
measured for crystals of NMDAR and conantokin-NMDAR cocrystals are expected to 
reveal the exact location of conantokin binding. Although the current resolution limit for 
NMDAR crystal diffraction is 4 A, crystals for the conantokin-receptor complex may 
perform better. Furthermore, even at 4 A resolution, information regarding the location of 
the conantokin binding site would be invaluable in guiding design of future domain 
constructs to better discern molecular interactions between conantokins and the NMDAR.
Conantokins are rich in gla residues. By analogy with the role of gla residues in other 
proteins, I suggest that one possible explanation for failure to detect molecular interaction
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between conantokins and NMDAR LBDs has something to do with removal of the LBD 
domains from cell membranes. Gla residues in proteins such as pro-thrombin are known to 
tether proteins to negatively charged groups on cell membranes via mutual interaction with 
bridging calcium ions25,26. Perhaps gla residues perform a similar function for conantokins. If 
such is the case, membrane-gla residue interactions may be essential for productive binding 
of conantokins to NMDARs. Support for this idea comes from mutagenesis studies which 
show that residues on the NMDAR that are critical for sensitivity to conantokin inhibition 
are located near the membrane when mapped onto the NMDAR crystal structure. Similarity 
with other gla-rich proteins and these mutagenesis studies suggest that conantokins may be 
tethered with the neuronal membrane during NMDAR binding.
A diagram of the membrane-tethered model for NMDAR binding is shown in 
Figure 4.11. In this scenario, combining energy realized by membrane association and energy 
realized from NMDAR interactions increases affinity of conantokins for NMDARs. In the 
absence of membrane association, overall binding energy is reduced, explaining why isolated 
LBDs showed interaction with conantokin. The membrane-tethered model could also 
explain why the concentration of conantokin required to observe behavioral effects in 
animal assays is lower than the concentration of conantokin required to inhibit NMDARs 
expressed on the surface of Xenopus oocytes. The energy component derived from 
membrane association would depend on membrane composition. Since oocytes and neurons 
have different membrane compositions, it is likely that binding affinity is also different. The 
binding affinity reduction incurred by nonnative membrane composition is probably less 
than that incurred by removal of the membrane altogether, explaining why conantokins 
inhibit NMDARs expressed on the surface of Xenopus oocytes but showed no molecular 







Figure 4.11: A hypothetical model of conantokin binding. The model illustrates conG 
(black spheres) bound to an NMDAR tetramer (cartoon, NR1 subunits grey, NR2 subunits 
red) embedded in a phospholipid bilayer (brown lines with phosphates as spheres). Residues 
on the NMDAR that influence conantokin sensitivity (blue spheres) are near the modeled 
conantokin-binding site. Glutamate (yellow spheres) is shown bound to the LBD. In this 
model, calcium ions could bridge conantokin to the membrane for increased binding energy.
Conclusion
At present, the mechanism of conantokin-NMDAR binding is still unclear. Still, it is 
likely that multiple protein domains of the NMDAR, and the membrane context of the 
NMDAR, each contribute to conantokin binding in some manner. Future studies on 
conantokin-NMDAR interactions will have to examine more complex possibilities for a 
conantokin-binding interface on NMDARs. Researchers should probe binding in more 
complete combinations of extracellular domains (e.g., ATD-LBD constructs), and assess the 
potential for conantokin interactions that require multimeric NMDAR structure. 
Fortunately, the exact molecular picture of binding will likely be revealed when a 
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CHAPTER 5
USE OF CONANTOKINS TO IDENTIFY NMDA RECEPTOR 
SUBTYPES IN LIVE NEURONS FROM MOUSE 
CEREBELLUM
Introduction
Understanding the molecular mechanisms that govern N-methyl-D-aspartate 
receptor (NMDAR) inhibition by conantokins has important implications for developing a 
toolset of subtype selective NMDAR inhibitors. A toolset of selective NMDAR inhibitors, 
in turn, has important implications for understanding the physiological role of NMDA 
receptors in the mammalian nervous system. As novel conantokins are discovered or 
developed, those with unique selectivity for NMDAR subtypes become new tools for 
studying NMDARs of the nervous system. Ultimately, a toolset of conantokins with 
specificity for all NMDAR subtypes would be expected to reveal which NMDAR subtypes 
are present in particular regions of the nervous system and offer insights into the 
physiological role of those receptors. To this end, this chapter describes the first use of 
selective conantokin peptides to reveal NMDAR composition in a large population of 
neurons from mouse cerebellum.
NMDARs o f  the cerebellum 
NMDARs are expressed throughout the central nervous system of mammals. 
Different NMDAR subtypes show unique spatial expression patterns and NMDAR subtype 
expression can change dramatically during development. Since the NR1 subunit is an
obligatory component of all NMDAR tetramers, NR1 is expressed ubiquitously throughout 
the brain during all stages of development1. In contrast, NR2 subunits have unique spatial 
expression patterns that change throughout development1-4. The restricted expression 
patterns, and the developmental changes that occur for NR2 expression, suggest that 
different NMDAR subtypes have specific developmental and physiological roles.
One region of the brain where developmental changes of NR2 subtype expression 
are particularly dramatic is the cerebellum. In murine cerebellum, NR2B is highly expressed 
at birth but drops to undetectable levels by adulthood5,6. Concomitant with the decrease in 
NR2B expression, expression of NR2C increases and persists into adulthood5,6. These 
developmental changes implicate NR2B NMDAR subtypes in formation of neuronal 
connections, and NR2C NMDAR subtypes in maintaining NMDAR-mediated excitatory 
neurotransmission in the cerebellum. Additionally, functional molecular properties of 
cerebellar NMDARs change developmentally in a manner that is consistent with a shift to 
NR2C NMDAR subtypes; mature neurons express NMDA receptors with low conductance 
and slow kinetics7,8.
Although NR2 subtype expression in the cerebellum changes dramatically through 
development, it is unclear how the transition from NR2B to NR2C occurs in individual 
neurons. Potential pathways for this transition include: NR2B expressing neurons start 
expressing NR2C and the cells transition through NR12-NR2B1-NR2C1 triheteromeric 
NMDARs; NR2B expressing neurons start expressing NR2C and cells contain a mixed 
population of NR12-NR2B2 and NR12-NR2C2 diheteromeric NMDARs; or a nascent 
population of neurons arises that express NR2C (but not NR2B) and contain NR12-NR2C2 
diheteromeric NMDARs, which ultimately replace NR2B expressing neurons. Determining 
which of these models is correct is, in part, a technical problem that arises from limitations
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of electrophysiology and lack of selective NMDAR pharmacology. Electrophysiological 
recordings provide information on single cells, and therefore mask potential diversity among 
cells. Therefore, alternative methods that facilitate observation of a mixed population of 
many neurons simultaneously would be beneficial. Fortunately, recent technical advances 
with calcium imaging provide the opportunity to observe large and diverse populations of 
neurons from the central nervous system. Also, the recent emergence of truly of subtype- 
selective conantokins provides tools that can identify the presence of certain NMDAR 
subtypes using calcium imaging.
Constellation pharmacology
Constellation pharmacology is a recently developed technique that allows the 
simultaneous functional characterization of hundreds neurons within a single experiment9. It 
uses calcium imaging, where a calcium-sensitive dye is trapped inside neurons and provides 
an indicator of intracellular calcium levels. Since many ion channels expressed in neurons are 
permeable to calcium, constellation pharmacology can be used to probe the ion channel 
composition of those neurons. Also, depolarization of the cell triggered by receptors that are 
not permeable to calcium generally results in activation of voltage-gated calcium channels, 
which allows for calcium impermeable channels to be studied as well. In all, thousands of 
neurons can be analyzed to provide characterization of the different neuronal subtypes and 
the frequency of those subtypes in particular areas of the brain.
The ability to define ion channel compositions of neurons with constellation 
pharmacology is made possible with pharmacological tools that selectively activate or inhibit 
specific ion-channel subtypes. Previous experiments applying constellation pharmacology 
have successfully defined neurons by their ion channel composition in both the dorsal root 
ganglion (DRG)9,10 and the central nervous system (CNS)11. These examples illustrate that
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constellation pharmacology is an effective method for understanding neuronal diversity, and 
cell-specific ion channel expression. However, these experiments have not thoroughly 
examined NMDA receptors and have been performed on select regions of the brain and 
spinal cord. Thus, combining constellation pharmacology with selective conantokin peptides 
is a natural progression in efforts to understand NMDARs of the mammalian nervous 
system. Additionally, extending constellation pharmacology to new regions of the brain 
deepens our scientific knowledge of neuronal organization in the CNS.
Methods 
Cerebellar cell preparations and culture 
The methods described for preparing cerebellar neurons were adapted from those 
previously described for CNS neurons of the ventral respiratory column11. Mice (WT 
C57BL/6) at postnatal day 7-14 were anesthetized on ice and sacrificed with decapitation per 
Institutional Animal Care and Use Committee (IACUC) approved protocols. The mouse 
head was pinned to a silicone-covered culture dish for dissection and removal of the 
cerebellum. Skin and connective tissue were removed to reveal the skull and the skull was 
pierced at the seam connecting hind and fore skull plates. After opening the skull, ice-cold 
artificial cerebro-spinal fluid (ACSF) pH 7.6 bubbling with carbogen was applied to the brain 
tissue every 2-3 minutes to keep tissue cold, moist, and oxygenated.
The hind skull was removed by clipping along the boundary between parietal and 
intraparietal skull bones to expose the midbrain and cerebellum. A single cut was made with 
a fresh razor blade above the cerebellum at a 20° below-vertical angle to remove the 
cerebellum, brainstem, and underlying tissue. The cerebellum was isolated from other tissue 
with a razor blade and transferred to a bath of ice-cold ACSF. The isolated cerebellum was
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dissected into 2 mm x 2 mm pieces. Cerebellar pieces were transferred to 900^L ice-cold 
Hank's balanced salt solution (HBSS), 100 ^L of 2.5 % wt./vol. trypsin was added, and the 
resulting mixture was incubated for 5 minutes at 37° C. Protease was removed through 
dilution by rinsing the cerebellar tissue 3x with 10 mL ice-cold ACSF and 1x with 4mL 
Eagle's minimal essential medium (MEM) supplemented with 10% vol./vol. FBS (HyClone), 
100 U/mL penicillin, 100 ^g/mL streptomycin, 1X Glutamax (Invitrogen), 10 mM HEPES 
pH 7, and 0.4% wt./vol. glucose.
Cerebellar tissue in MEM media was triturated with a series of four fire-polished 
pasture pipettes of decreasing diameters until the solution was cloudy with few visble 
chunks. The cell suspension was then diluted 1:5 for plating. Twenty ^L of the diluted cell 
suspension was pipetted into the center of a silicone donut affixed to a poly-lysine coated 
24-well tissue culture plate. Cells were allowed to adhere to the plate for 1 hour in a 37 °C 
incubator prior to flooding the well with 1 mL MEM containing supplements. Wells not 
containing cells were filled with sterile distilled water to increase humidity during culture. 
Adhered cells in MEM media were cultured overnight for 16-20 hours in a 37 °C incubator 
with 5% CO2.
Calcium imaging
Calcium imaging was performed as previously described9-11. Briefly, cerebellar 
neurons were incubated with Fura-2-acetoxymethyl ester in MEM culture media for 1 hour 
following overnight culture. At initiation of experimental imaging, the Fura-2/MEM media 
was replaced with ACSF pH 7.4 at room temperature. Fluorescence emission intensity was 
measured at wavelength 510 nm with alternating excitation wavelengths of 340 and 380 nm. 
Data were recorded as the ratio of emission intensity measured for each excitation
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wavelength (340:380 ratio) per standard calcium imaging techniques. Deflections of the 
340:380 ratio are indicative of changes in cytosolic calcium levels with an increasing ratio 
representing an increase of calcium.
Data analysis
Calcium imaging data were analyzed using the imaging software NIS-elements 
(Nikon) and using an R-based program, ProcConstPharm, written by Dr. Kevin Chase 
(University of Utah, departments of biology and mathematics). In ProcConstPharm, cell 
phenotypes were defined using a binary scoring system of response (1) or no response (0) to 
various chemical inputs. Cluster analysis was used to group cells by response phenotype and 
calculate cell-class percentages. Quantitative analysis of peak heights was performed using 
ProcConstPharm. Peak heights were calculated by subtracting baseline from the maximum 
response within a user defined response window. ProcConstPharm facilitated an unbiased 
scoring of cell phenotypes using baseline-corrected data and user-defined peak recognition 
criteria (e.g., peak height and peak signal to noise). Cell culture images were produced with 
NIS-Elements (Nikon), individual cell traces were generated with ProcConstPharm, and 
dose-response curves were plotted with Prism6 (GraphPad Software, La Jolla, California 
USA).
Results
Culture o f  dissociated cerebellar neurons 
Slight modification of protocols developed for culturing neurons of the ventral 
respiratory column (VRC)11 led to viable cerebellar neuron cultures. Figure 5.1 shows the 
typical appearance of cerebellar neurons following tissue dissociation and overnight cell 
culture from a postnatal day 7 (P7) mouse. The neurons of the cerebellum showed similar
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Bnghtfield Fluorescence Merge
Figure 5.1: Culture of cerebellar neurons from P7 mouse. The bnghtfield, fluorescence, 
and merge images of cultured cerebellar neurons show a high proportion of small cells. 
These results were typical when culturing cerebellar neurons.
morphology to those of the VRC, but exhibited a higher frequency of small neurons that 
were less than 100 ^m2 in cross-sectional area. In contrast to dorsal-root ganglion cultures, 
the cerebellar cultures did not contain very large neurons >400 ^m2 and generally neurons 
had cross-sectional areas that were less than 350 ^m2.
Neuronal phenotypes are defined with agonist challenge experiments 
To define different neuronal phenotypes of the cerebellum, an agonist challenge 
protocol identified glutamatergic and cholinergic neurons. Cluster analysis defined cell 
classes according to how each neuron responded to various glutamatergic and cholinergic 
agonists including NMDA, glutamate, glycine, acetylcholine, carabamylcholine (carbachol), 
and nicotine. Figure 5.2 shows representative traces from single cells that illustrate the 
pattern of response for the 12 most frequently encountered neuronal phenotypes of the 
cerebellum. In most cases, neurons responded only to glutamatergic inputs (34.1% of cells) 
or responded only to cholinergic inputs (15.5% of cells). However, some neurons responded 
































Figure 5.2: Diversity of glutam atergic and cholinergic neurons in mouse cerebellum.
Representative traces for the 12 most-common response phenotypes and frequencies of 
those phenotypes are shown. Agonist application protocol is shown at the bottom with the 
following abbreviations: NMDA=200^M NMDA/20^M D-serine, GLUT=300^M 
glutamate, GLY=200^M glycine, ACH=1mM acetylcholine, NIC=200^M nicotine, 
CARB=1mM carbamylcholine, K+=30mM potassium, K+GAB=30mM potassium/1mM 
GABA. Each agonist was applied for 10 seconds. Group frequencies were calculated from 8 
experiments, 5 mice, and 2,866 neurons.
1
The most frequently encountered neuronal phenotypes were glutamatergic and 
responded to strongly to NMDA / D-serine, and responded to depolarization (Figure 5.2, 
group 1). The second most-frequent neuronal phenotype only responded to depolarization 
(Figure 5.2, group 2). Presumably group-2 neurons would respond to other excitatory 
neurotransmitters that are not glutamatergic or cholinergic (e.g., serotonin). The third most 
frequent phenotype generally responded weakly to NMDA and responded more strongly to 
cholinergic agonists and to depolarization (Figure 5.2, group 3). Less frequent glutamatergic- 
only phenotypes were also observed and can be seen in Figure 5.2, groups 4, 8, 9, 10, and 11. 
Also, less frequent cholinergic-only phenotypes were observed and are shown in Figure 5.2, 
groups 5 and 6. There were two neuronal phenotypes that responded to both glutamatergic 
and cholinergic agonists (Figure 5.2, groups 7 and 12).
In addition to the neuronal phenotypes shown in Figure 5.2, 4.6% of cells did not 
respond to any agonists tested in this protocol. These are likely to be glial cells, which 
support cells of the nervous system but generally do not express ion-channels or otherwise 
participate in neurotransmission. The remaining 31.8% of cells that did not fit into already 
described phenotypes were placed into a miscellaneous group. The miscellaneous group 
included cells that died during the experiment, cells with large shifts in baseline, and cells 
with infrequently observed response patterns. Infrequent response patterns were generally 
seen in less than 1% of all cells and were found in less than four of the six experiments 
performed. The high frequency at which neurons were placed in the miscellaneous category 
by automated response detection in ProcConstPharm merits some comments. In order to 
confidently assign cells to a particular phenotype and avoid misdiagnosis, there had to be 
clear evidence of a response-pattern match. Many of the neurons assigned to the 
miscellaneous cell category probably could be assigned to a particular phenotype if criteria
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for a response-pattern match were more relaxed. However, this would create the situation of 
a particular cell being matched to more than one phenotype or even being matched to the 
wrong phenotype. To avoid such ambiguity, and to avoid a source of bias, I decided to keep 
the pattern-matching criteria stringent and not further consider cells that had been assigned 
to the miscellaneous category.
To further investigate neuronal phenotypes found with constellation pharmacology, I 
undertook experiments using agonists and antagonists with selectivity for individual ion 
channel subtypes. The glutamate responses seen in Figure 5.2 could have come from 
activation of AMPA or kainate type glutamate receptors. Thus, I utilized AMPA as a 
selective agonist to determine which receptor was responsible for glutamate responses. In 
these experiments, all cells that responded to glutamate also responded to AMPA, and the 
responses for glutamate and AMPA were of similar magnitude (data not shown). Thus, it 
appears AMPA-type glutamate receptors are the predominant non-NMDA receptor in 
cerebellar neurons.
I was surprised to observe cells that responded to acetylcholine (ACh) and 
carbamylcholine (carbachol) but not to nicotine (groups 6, 7, 12). Carbachol is often used as 
a more stable substitute for ACh and is known to activate nicotinic acetylcholine receptors. I 
hypothesized that the ACh/carbachol-responding cells might contain muscarinic ACh 
receptors. To test this hypothesis, I utilized the muscarinic acetylcholine receptor antagonist 
atropine. Atropine completely blocked ACh response in the ACh/carbachol-responsive cells, 
but did not completely block ACh response in ACh/nicotine/carbachol-responsive cells 
(data not shown). Therefore, cells in groups 6, 7, and 12 contain muscarinic acetylcholine 
receptors but not nicotinic acetylcholine receptors. Altogether, the results show that 12 or 
more neuronal cell types exist in the cerebellum, and these cell types exist in different
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frequencies and can be differentiated by neuronal phenotypes displayed during constellation 
pharmacology experiments that reflect the combinations of ion channels each cell expresses.
I was curious to compare the cell types identified by constellation pharmacology with 
cell types defined by other classification systems. Cell types of the cerebellum have been 
previously defined based on network connectivity, cell morphology, and cell-body size12,13. 
For example, Purkinje neurons are large and highly branched, while granule neurons are 
small with limited branching13. Although dendritic branching is lost upon dissociation, I 
believe cell body size in culture is an accurate reflection of cell body size found in the brain. 
Consequently, I examined cell cross sectional area from cerebellar cultures to see if 
correlations with phenotype could be drawn.
The distribution of cell areas for each of the major neuronal phenotypes identified 
for P7 mouse cerebellar neurons is presented in Figure 5.3. The observed range of cell areas 
for each phenotype was broad. The majority of cells in all groups were found to have cell 
areas between 50^m2 and 200^m2, but some larger cells (cell area >200 ^m2) were also 
present. Interestingly, groups that responded to cholinergic inputs consistently had larger 
mean cell areas than neurons that responded only to glutamatergic inputs. However, the 
broad range of cell sizes characterizing each of the neuronal phenotypes defined by 
constellation pharmacology indicates cell area should not be used as an indicator of neuron 
type, at least not for small cells derived from mouse cerebellum. In contrast to the results 
presented here, dorsal root ganglion neurons from the peripheral nervous system fall into 
distinct size categories that strongly correlate with phenotype (Olivera Lab, unpublished 
data). Examining cerebellar neurons from older mice that are more developed would 
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Figure 5.3: Cell areas of neuronal groups defined with constellation pharmacology.
Individual cell area data points for neurons within each group are shown as grey dots. Mean 
cell areas for each group are shown (center horizontal black bar) along with 95% confidence 
intervals (upper and lower horizontal bars).
Conantokin inhibition o f  NMDA response in cerebellar neurons 
In agonist challenge experiments, a majority of neurons from the cerebellum 
responded to the agonists NMDA/D-serine, indicating the presence of NMDARs. I sought 
to characterize the NMDAR composition in these neurons using the conantokin peptide 
conRl-B. ConRl-B is highly potent and selective for NR2B containing NMDARs with an 
IC50 value of 0.1 ^M on NR2B, and IC50 values greater than 10 ^M on all other NMDAR 
subtypes14. The protocol for these experiments incorporated multiple NMDA/D-serine 
pulses and pre-incubation with conRl-B at various concentrations. Representative traces 
from experiments performed on cerebellar neurons of a P7 mouse are shown in Figure 5.4.
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Figure 5.4: ConR/-B inhibits NMDA response in cerebellar neurons. Calcium imaging 
traces depicting the effects of conRl-B on neurons from the cerebellum. All NMDA 
responsive neurons were inhibited to some degree by conKi-B. K+=30mM potassium, 
GLUT=300^M glutamate, ACH=1mM acetylcholine, NMDA=200^M NMDA/20^M D- 
serine. Magnesium free conditions were used starting just after the ACH pulse (indicated by 
black bar).
The results of this experiment showed that all NMDA-responsive neurons were 
blocked by conK/-B in a dose-dependent manner. This suggests that all NMDA responsive 
P7 cerebellar neurons express NMDA receptors containing the NR2B subunit. Interestingly, 
at 10 ^M conK/-B some cells were completely blocked while others had residual calcium 
influx. The cells with residual calcium influx even in the presence of saturating conK/-B may 
be expressing additional NMDAR subtypes. These might have a non-NR2B population of 
diheteromeric NMDARs that mix with NR2B diheteromeric NMDARs, or these may 
express triheteromeric NMDARs that contain NR2B and another NMDAR subunit. Of 
note, no NMDA responsive neurons from P7 mouse cerebellum were conK/-B insensitive, 
which indicates a strong NR2B-mediated component to NMDAR signaling in cerebellar 
neurons of the developing mouse.
Following observations that conantokins could be used to examine NMDARs of live 
neurons, I wondered how the effect of conantokins on those neurons would compare to the 
effect of conantokins observed in vitro by means of electrophysiology using Xenopus oocytes 
expressing NMDARs. To compare results from these two experimental techniques I created 
dose-response curves for conantokins acting on living neurons, which could be compared to 
dose-response curves for conantokins acting on oocytes.
Using ProcConstPharm, peak heights were extracted for NMDA-responsive neurons in 
the conantokin assay. The data were normalized to the first NMDA pulse, plotted, and fit to 
the Hill equation (Figure 5.5). NMDA responsive neurons from the cerebellum exhibited a 
spectrum of sensitivities to conR/-B with IC50 values ranging from 0.2-2.8 ^M. The mean 
IC50 for conRZ-B inhibition of NMDAR response was 0.64±0.31 ^M. Hill coefficients 
ranged from -1.60 to -0.43 with a mean value of -0.92±0.19 (Figure 5.6), indicating that 
conantokin inhibition of NMDARs is not a cooperative process.
To determine if sensitivity to conRZ-B, as assessed by IC50, correlated with neuronal 
phenotype, the NMDA responsive phenotype was further segregated on the basis of 
response patterns involving glutamate and acetylcholine. This subdivision of NMDA 
responsive cells resulted in four types: those that responded to NMDA only, those that 
responded to NMDA and glutamate, those that responded to NMDA and acetylcholine, and 
those that responded to all three agonists, NMDA, glutamate, and acetylcholine. The mean 
IC50 value for conRZ-B inhibition of NMDA response in each of these groups was not 
statistically different (data not shown). Therefore, various neurons that contain NMDARs 
appear to express the same NMDA receptor subtypes regardless of co-expression of other 




Figure 5.5: Curve fits for conR/-B inhibition of NMDA response in cerebellar 
neurons. Peak heights were normalized to the first NMDA pulse and plotted as a function 
of log[conR/-B](M). Curve fits were produced using the Hill equation for normalized data 
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Figure 5.6: Distribution of IC50 values and H ill coefficients for conR/-B inhibition of 
NMDA response in cerebellar neurons. The IC50 values and Hill coefficients for conR/-B 
inhibition of NMDARs in live cerebellar neurons are close to the values observed for NR2B 
NMDARs expressed in vitro.
Developmental changes in NMDAR subtype expression
Because NMDAR subtype expression in the cerebellum is known to change during 
brain development1,5,6,15,16, I wondered how the effects of conRl-B would compare for 
neurons harvested from young and from older mice. Unfortunately, there are significant 
technical challenges associated with the culture of neurons from adult mice. Generally, only 
dead or nonresponsive cells were observed when dissociated cerebellar neurons were 
prepared from a P21 mouse. However, slight modifications of protocols and the use of 
intermediate-aged P14 mice resulted in improved cultures with NMDA responsive, living 
cells. The modified protocol incorporated an altered culture media that contained a 50 % 
MEM media and 50% Neurobasal media augmented with glial cell line-derived neurotrophic 
factor (GDNF). GDNF is a hormone known to promote neuronal growth and axon 
sprouting17,18.
Calcium imaging traces from an experiment using the modified culture protocol on a 
P14 mouse are presented in Figure 5.7. Similar to what was observed for P7 neurons, most 
NMDA-responsive cerebellar neurons from the P14 mouse showed sensitivity to conRl-B. 
Furthermore, the sensitivity was similar to that observed for P7 neurons with IC50 values 
centered around 1 ^M. However, in addition to conRl-B sensitive neuorns, a distinct 
population of NMDA-responsive and conR/-B insensitive neurons were also observed (4 of 
100 cells). This NMDA-responsive and conRl-B insensitive phenotype was not observed in 
P7 cerebellar neurons, suggesting that between developmental stages of P7 and P14 a new 
NMDAR subtype is expressed in cerebellar neurons. Taken together with previous results 
from in situ hybridizations, which showed increased levels of NR2C MRNA in the 
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Figure 5.7: Phenotypes observed for P14 cerebellar neurons. Three cell phenotypes 
defined by NMDA response and sensitivity to conRZ-B. A: NMDA responsive neurons that 
were completely blocked by 10^M conRZ-B. B: NMDA responsive neurons that were 
incompletely blocked by 10^M conRZ-B. C: NMDA responsive neurons that were 
insensitive to block by conRZ-B. Traces in panel C report the behavior of neurons that no 
longer express NR2B NMDAR subtypes and that likely express NR2C NMDAR subtypes.
Discussion
Results summary
In this chapter, constellation pharmacology was used to define the glutamatergic and 
cholinergic populations of neurons found in mouse cerebellum. Using an agonist challenge 
assay, the majority of neurons in mouse cerebellum were found to be small, glutamatergic 
neurons. These neurons were further subdivided based on responses to glutamate, NMDA, 
glycine, and depolarization. The cholinergic neurons of mouse cerebellum were generally
larger in size and could be subdivided based on responses to acetylcholine, nicotine, 
carbachol, and depolarization. For NMDA-responsive glutamatergic neurons, NMDAR 
composition was examined using conantokin peptides. These experiments revealed that in 
young mice all NMDA responsive neurons were sensitive to inhibition by conK/-B. 
Therefore, young mice express NR2B NMDAR subtypes. In older mice, a population of 
conK/-B insensitive neurons was discovered that presumably express the NR2C NMDAR 
subtype. Thus, neurons in older developing mice express a mixture of NR2B and other 
NMDA receptor subtypes.
ConsteUation pharmaco/ogy 
Calcium imaging is a technique that has been used for decades to measure changes in 
cytosolic calcium levels19. Since many different ion channels are permeable to calcium20, 
calcium imaging is useful for studying ion channel composition in live cells21. Recently, 
constellation pharmacology has shown its utility in understanding ion channel compositions 
in large populations of dissociated neurons9-11,22. These studies illustrate that the fusion of 
calcium imaging with pharmacological agents can define ion channel composition in single 
neurons.
This dissertation has advanced constellation pharmacology in two distinct ways. 
First, I have presented the initial characterization of cerebellar neurons using constellation 
pharmacology, thereby extending the technique to a new area of the brain. Second, I have 
demonstrated the first use of conantokin peptides to define NMDAR subtypes of living 
neurons at different stages of development. These experiments provide the first examination 
of NMDAR subtypes in a large and diverse set of neurons and set forth a new path for 
understanding the distribution and physiological role of different NMDAR subtypes.
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Diversity o f  cerebeiar neurons
Agonist challenge experiments revealed that the most frequently encountered 
neurons of the cerebellum responded to NMDA/D-serine and membrane depolarization, 
and had small cell areas. Anatomical studies of the cerebellum have identified granule cells as 
the most common and smallest cells of the cerebellum12. Also, granule cells receive 
glutamatergic inputs that are in part transmitted by NMDA receptors23-25. I hypothesize that 
group 1 neurons classified by constellation pharmacology correspond with granule cells of 
the cerebellum. Also, it has been shown that glutamate receptors expressed in cerebellar 
granule cells can include AMPA, kainate, and metabotropic receptors24,26-29. Consequently, I 
further hypothesize that the subset of small neurons belonging to groups 4, 9, and 10 
defined by constellation pharmacology represent additional populations of granule cells. To 
test these hypotheses, further experiments will need to definine the exact mixture of 
glutamate receptors in the phenotypic groups and correlate those groups to cells of known 
anatomical loci. Hopefully, future experiments will elucidate how each phenotype defined by 
constellation pharmacology presented here is related to known cerebellar cells that include 
granule, stellate, basket, Golgi, and Purkinje neurons.
Analysis o f  ce// areas
Since specific neurons of the cerebellum are known to have well defined sizes (e.g., 
granule cells are small, Purkinje cells are large), I expected that phenotypic groups from 
calcium imaging would fall into tightly grouped size classes. However, I observed a broad 
range of cell sizes within each phenotypic group, which presents a challenge for connecting 
cell phenotype defined by constellation pharmacology to known cerebellar neurons.
It may be the case that dissociation protocols alter the size of neurons. However, I 
believe significant changes to cell body size are unlikely with the current protocols. It is also
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possible that many cells have not matured to their final sizes in P7 mice, which could cause 
variability of cell sizes within groups. Nonetheless, it would be helpful to explore less 
intrusive methods of cell dissociation, and to examine cell size distribution in older mice. 
Maybe stronger phenotype-cell size correlations will be found in fully developed animals.
Another hypothesis that can explain diversity of cell sizes within a group is that there 
may be phenotypic variation for any given cell type (e.g., granule or Purkinje cell). For 
instance, Purkinje cells as a class could exhibit multiple phenotypes as defined by agonist 
challenge protocols. If this hypothesis is true and diverse neuronal phenotypes exist within 
the population of Purkinje neurons, which are highly homogeneous in morphology, it would 
be an exciting and unexpected result that could change current views of what defines neuron 
cell identity. In order to test this hypothesis, experiments that allow correlation of 
constellation pharmacology phenotypes to cell types in the intact cerebellar milieu will be 
necessary.
From dissociated cells to intact networks
In order to draw stronger conclusions with constellation pharmacology there is need 
to associate specific neurons from specific brain loci to functional phenotypes defined by 
calcium imaging in dissociated culture. Consequently, cell-specific markers that allow 
positive identification of the same neurons in slice and in dissociated culture preparations are 
desired. Such markers would allow correlation of cell phenotype observed in constellation 
pharmacology to cell type based on anatomical location and connectivity. Accordingly, 
experiments are being pursued to identify specific populations of neurons using fluorescent 
markers. Scientists in the Olivera lab are currently exploring the use of green-fluorescent 
protein expression controlled by cell-specific promoters. In a second approach, researchers 
are using fluorescent antibodies to identify cell-specific proteins. Successful implementation
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of these techniques will lead to pivotal discoveries regarding ion channel composition in 
specific neuron populations and allow for the correlation of cell phenotype observed in 
constellation pharmacology to cell type based on anatomical location and connectivity.
Possible sources o f  NMDAR heterogeneity in cerebellar neurons
Experiments exploring conantokin inhibition of NMDA response in cerebellar 
neurons showed that conRl-B inhibited responses in all neurons of P7 mice with a mean IC50 
of 0.6 ^M. Under the assumption that conantokin affinity is similar for NMDARs in 
oocytes and NMDARs in neurons, this indicates that during the P7 developmental stage all 
neurons express NR2B NMDAR subtypes. Interestingly, there was a broad distribution of 
IC50 values, which may indicate that not all cerebellar neurons contained identical NMDAR 
compositions.
One explanation for the broad IC50 distribution is that different NR1 splice variants 
are found in these neurons. It has been documented that differences in the NR1 splice 
variants can have effects on conantokin inhibition30,31. Another explanation is that other 
NR2 and/or NR3 subunits coassemble with NR2B to create triheteromeric receptors that 
are differentially sensitive to conRl-B. Previous work has shown that triheteromeric 
NMDARs exist in the cerebellum32,33. However, the effects of subtype selective conantokin 
peptides on triheteromeric NMDARs are yet to be examined. This should be explored by 
exploiting systems that can enrich for triheteromeric NMDARs.
In order to decode the underlying meaning of the results from conRl-B inhibition of 
cerebellar neurons and to further define NMDAR subtypes, there is need to employ 
additional NMDAR inhibitors with selectivity profiles that differ from conRl-B. Some 
possibilities include conR, which inhibits both NR2A and NR2B containing NMDARs34 and
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Quinazolin-4-one derivatives, which inhibit NR2C and NR2D containing NMDARs35. 
Additionally, magnesium sensitivity could be used to identify NR2A and NR2B containing 
receptors, and other subtype-dependent properties of NMDARs could be exploited to 
decipher exact subunit combinations. These include channel kinetics and sensitivity to 
various effectors including zinc and pH.
Examining deve/opmenta/ transitions in NMDAR subtype expression 
The conantokin inhibition experiments on P14 mice revealed a population of conK/- 
B insensitive neurons that were not found in younger mice. Taken in the context of previous 
works, these cells are likely expressing NMDARs that contain the NR2C subunit. However, 
it is still unclear how the switch from NR2B to NR2C occurs. Do cells transition through 
expression of triheteromeric NR12/NR2B/NR2C receptors, do transitional cells express a 
mixture of NR12/NR2B2 and NR12/NR2C2 diheteromers, or are there newly integrated cells 
that express NR12/NR2C2 diheteromeric receptors? To answer these questions additional 
work needs to be done, and identifying exact receptor combinations may require a more 
sensitive technique than calcium imaging. Perhaps calcium imaging combined with 
electrophysiology of the same cell populations can provide answers on subunit composition; 
electrophysiology allows sensitive measurement of channel properties that can lead to 
determination of exact subunit compositions.
Summary
The work described here was the first to demonstrate conantokin inhibition of 
NMDAR responses in a large and diverse population of live neurons. The findings revealed 
that all cerebellar neurons in P7 mouse were sensitive to inhibition by conK/-B, suggesting 
that those cells expressed NMDARs containing the NR2B subunit. In P14 mice, however, a
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population of conRl-B insensitive neurons was observed. These most likely expressed 
NMDARs lacking the NR2B subunit, but containing the NR2C subunit. Ultimately, the 
results show that cerebellar neurons of young mice have a dominant population of NR2B 
NMDAR subtypes, and that as the mouse develops a population of neurons expressing a 
different NMDAR subtypes arises. The results are consistent with expectations drawn from 
previous work examining mRNA levels in cerebellar tissue. This consistency suggests that 
the techniques described herein will be useful for studying unknown properties of NMDARs 
in single neurons of the mammalian brain. Clearly, the combination of conantokin peptides 
and constellation pharmacology presents a new frontier for studying the physical architecture 
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Perspectives on this dissertation 
Structural studies on conantokins 
Chapter 2 described the discovery and characterization of conantokins from Conus 
bocki. The conantokins discovered were found to have highest affinities for NR2D NMDAR 
subtypes and the nuclear magnetic resonance (NMR) structure of conBk-B was determined. 
The most important results were the discovery of an ultra-short 9-residue conantokin, the 
finding that conantokins can have preference for NR2D NMDAR subtypes, and the 
identification of residues 5, 6, and 8 as determinants of selectivity.
Chapter 3 described NMR structure determination for conRl-B from Conus rolani. 
ConRl-B is the most NR2B-selective conantokin yet discovered and structure determination 
revealed a helix-kink-helix motif that is distinctive among known conantokin structures. In 
conRl-B, a hydroxyproline residue at position 10 caused the kinked conformation. 
Interestingly, this conformation does not have strong influence on NR2B selectivity; it has 
been shown that mutating this residue does have small effects on toxin potency and 
selectivity1. Nonetheless, the structure of conRl-B was striking, and with structural 
comparisons provided insights into mechanisms of conantokin selectivity.
Comparison of the conBk-B and conRi-B structures, together with mutational 
analysis presented here and elsewhere, indicate that NMDAR selectivity in conantokin 
peptides is determined by the combination of amino-acid residues near the amino-terminus. 
For conantokin peptides, the assemblage of residues at positions 5, 6, 8, and 10 govern 
selectivity. Of these residues, no single residue can confer selectivity by itself. Rather, the 
combination of residues, and the context in which these are found, determines subtype 
selectivity in conantokin peptides.
The conclusions from Chapters 2 and 3 have important implications for the future 
of conantokin and NMDAR research. Firstly, the discovery of the NR2D-preferring 
conantokins from Conus bocki suggests that other conantokins with selectivity for NMDAR 
subtypes beyond NR2B exist and are likely to be found with continued searching. Future 
investigations into different species of Conus will likely result in discovery of novel 
conantokins with selectivity for additional NMDAR subtypes Secondly, the structure-activity 
relationships seen for conBk-B and conRi-B indicate that the first 10 residues of conantokins 
should be a focus for development of increasingly selective conantokins. I anticipate that 
systematic mutational scanning near the amino terminus in conantokins will provide new 
insights into the combinations of amino acids that lead to subtype selectivity. Thirdly, the 
discovery of a 9-residue conantokin and the importance of residues near the amino terminus 
imply that short conantokin analogs should be more thoroughly investigated. Shorter 
conantokins may be easier to work with and may be more translatable into medicine. Ideally, 
the findings in Chapters 2 and 3 will guide discovery and development of novel conantokins 
with selectivity for all NMDAR subtypes. Subsequently, a panel of conantokin peptides with 
selectivity for all NMDAR subtypes can become tools that will be utilized to examine 
NMDAR subtypes and their physiological roles in the mammalian nervous system.
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Biochemical analysis o f  NMDAR LBDs 
Chapter 4 described the cloning, expression, purification, and biochemical analysis of 
NMDAR ligand binding domains (LBDs). The primary findings were that soluble NMDAR 
LBD proteins could be heterologously expressed in bacteria and purified for NR1, NR2A, 
NR2B, and NR2D subtypes, that the LBD proteins were active in binding known ligands, 
and that conantokin peptides did not show strong interactions with the LBD domains.
Although results from conantokin binding assays were negative, insights into the 
mechanism of conantokin-NMDAR interaction can still be drawn. One explanation for lack 
of interaction between conRl-B and the LBD derived from NR2 subunits is that an 
additional NMDAR domain is required for conantokin interaction (e.g., the ATD or the 
NR1 subunit). This hypothesis has led the Horvath lab to create NMDAR ATD-LBD 
constructs and systems that co-express the NR1 subunit-derived protein together with the 
NR2 subunit proteins. However, it is also possible that conantokin binding requires a 
complete NMDAR tetramer, or that conantokins have more complex associations with both 
NMDARs and neuronal membranes. Additionally, proteolysis and chromatography 
experiments described in this dissertation would have only revealed a tightly bound 
conantokin-NMDAR complex. Therefore, the negative results described in Chapter 4 do no 
rule out the possibility that a weak conantokin-LBD interaction indeed exists. If this is the 
case, crosslinking studies could be used to examine such weak conantokin-LBD association 
and map the binding interface.
Although there are many techniques that can be used to investigate conantokin- 
NMDAR interactions, the most direct approach would be through collaboration with the 
Furukawa group, who recently published the crystal structure of the NMDAR NR12-NR2B2 
tetramer2. In theory, going from the tetrameric NMDAR crystal structure to cocrystal
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structure bound to conantokin should not be exceedingly difficult. Potentially, conantokin 
peptides could be soaked into crystals obtained from a repeat of published protocols. If a 
soaking approach is unsuccessful, additional crystal trials could be pursued. A cocrystal 
structure of the NMDAR tetramer in complex with conantokin would be extremely rich in 
information. Assuming the structure was high resolution, it would reveal mechanisms of 
NMDAR inhibition, elucidate the conantokin-binding site, show which NMDAR domains 
and subunits are influenced, and divulge specific contacts that govern subtype selectivity in 
conantokins. Such discoveries would rapidly advance development of conantokin peptides 
with selectivity for each of the NMDAR subtypes.
Defining NMDAR composition in live neurons with conantokins 
Chapter 5 employed the NR2B selective conRl-B to examine NMDAR receptor 
subtypes in individual neurons of developing mouse cerebellum. These investigations 
revealed that all NMDA responsive cerebellar neurons expressed the NR2B NMDAR 
subtype at postnatal day 7 (P7) and that a population of cells expressing a different NMDAR 
subtype had developed by postnatal day 14 (P14). The discovery of functional NR2B 
NMDAR subtypes at postnatal day 7 (P7) is consistent with previous work that has shown 
NR2B mRNA at this developmental stage using in situ hybridization3,4. Therefore, the results 
indicate that dissociated neurons functionally express the same ion-channels as those 
inferred from detection of mRNA in vivo. Previous studies have also shown that expression 
of NR2C in the cerebellum is very low at birth, but increases into adulthood to become the 
predominant NMDAR subtype3-6. When taken in the context provided by these studies, the 
observation that conRl-B insensitive neurons were found at P14 suggests that a population 
of NR2C-expressing neurons begins to form in the developing mouse cerebellum. To 
further explore this hypothesis, additional NMDAR pharmacology should be applied with
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calcium imaging to confirm or rule out the presence of the NR2C NMDAR subtypes in 
cerebellar neurons of older mice. To extend the findings, the mechanism by which NR2C 
becomes dominant could be explored. It is unknown whether NR2C is expressed in the 
same, or different, cells than those expressing NR2B, and this is a question that could be 
answered with the techniques described in this dissertation.
One of my questions was whether inhibition of NMDAR response in cerebellar 
neurons by conantokins was similar to conantokin inhibition of heterologously expressed 
NMDARs in Xenopus oocytes. Consequently, dose-inhibition curves for conRi-B on 
cerebellar neurons were examined and compared to previously published results that used 
oocytes. The IC50 values for conRi-B inhibition of NMDA response at P7 was found to 
range from 0.2 to 2.8 ^M. ConRi-B has an IC50 of 0.1 ^M on NR12-NR2B2 diheteromers 
and an IC50 > 100 ^M for other diheteromeric combinations expressed in Xenopus oocytes1. 
Therefore, it appears that in cerebellar neurons, all cells express some type of NR2B 
containing NMDAR. However, the range of sensitivities may suggest that different 
combinations of NMDAR subtypes may be present in these neurons. Under the assumption 
that conRi-B can inhibit triheteromeric receptors that contain the NR2B subunit, the 
spectrum of observed IC50 values hint that P7 cerebellar neurons may contain triheteromeric 
receptors with just one NR2B subunit.
Because previous studies have revealed the presence of triheteromeric NR12-NR2A- 
NR2B and NR12-NR2B-NR2D receptors7-9, it could be the case that the developing 
cerebellum may contain NR12-NR2B-NR2C triheteromers. For young mice in my 
experiments, some cells were observed that had residual NMDA response at the highest 
conRi-B concentrations tested. The residual calcium signal could be mediated by 
triheteromeric NMDAR subtypes, or it could be that cells express additional NMDAR
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subtypes that do not contain the NR2B. Overall, it appears that within an individual cell 
there is probably functional expression of multiple NMDAR complexes that differ in 
subunit composition. Whether these differences are manifested through triheteromeric 
receptors or through co-expression of multiple diheteromeric receptors will need to be more 
thoroughly investigated.
In cerebellar neurons observed with calcium imaging, multiple NMDAR variants 
probably coexist. Based on in situ hybridizations, these could include NR12-NR2B2, NR12- 
NR2C2, NR12-NR2Br NR2Q, and possibly receptors containing NR2A subunits. 
Opportunely, the emerging availability of selective conantokin peptides paired with 
constellation pharmacology, electrophysiology, and other techniques, is creating a situation 
where researchers will be poised to decipher NMDAR subunit combinations in living 
neurons. These findings will extend the ability of future neurobiologists to examine the 
physiological role of NMDARs.
Developing conantokins as tools f o r  science and medicine
The importance of developing a toolkit of highly selective NMDAR inhibitors 
cannot be overstated. This dissertation has delineated structural themes for conantokins, 
provided mechanistic insights explaining conantokin selectivity, revealed that conantokins 
require more than the LBD of NMDARs for high affinity binding, and illustrated the utility 
of conantokins for examining NMDAR subtypes in live neurons. Cumulatively, these results 
will contribute to developing a needed toolkit for investigating NMDAR subtypes in the 
nervous system. Furthermore, the selectivity of conantokins as NMDAR inhibitors makes 
them potential drug leads. Various NMDAR inhibitors with lower selectivity have gone 
through clinical trials for the treatment of stroke, brain injury, Huntington's disease, epilepsy, 
seizure, and Alzheimer's disease, and many have failed due to disruption of normal NMDAR
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activity10-13. Consequently, the key to medical applications may rest on the availability of truly 
selective conantokins or conantokins derivatives. Highly selective conantokins, such as 
conRl-B, may prove to be practical and therapeutic for treatment of neuropathologies 
because high selectivity means unintended targets will be avoided, thus reducing the risk of 
unwanted side effects.
Perspectives on exploring Conus venoms 
Conantokins are one of many conotoxins found in Conus venom, and the techniques 
used to discover interesting conantokins can be applied to all conotoxin families. For 
instance, Chapter 2 illustrated the use of molecular phylogeny to identify conantokin 
peptides from Conus bocki with desired properties (e.g., NR2D potency). Molecular 
phylogeny as a guide for exploration of Conus venoms expedited the discovery of useful 
compounds and has proven its worth by providing conotoxins of particular interest14-16. With 
more than 500 species of cone snails, more than 10,000 venomous snails, and numerous 
toxins within each species, there are too many toxins for a comprehensive examination. 
However, with the current state of conotoxin research, the use of molecular phylogeny to 
predict which Conus species will have peptides of specific function should lead to many 
scientific breakthroughs. Furthermore, the rates of discovering conotoxins with usefulness in 
science and medicine are anticipated to increase in the forthcoming decades as the ability to 
predict where useful conotoxins will be discovered improves.
Perspectives on constellation pharmacology 
Neuronal profiling with calcium imaging 
Although calcium-imaging techniques have been used for decades to observe 
increases in intracellular calcium concentrations of neurons17-20, improvements in calcium
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sensitive dyes and optical techniques are leading to new frontiers in neuroscience. Recently, 
constellation pharmacology provided the first demonstration that large and diverse 
populations of neurons could be analyzed simultaneously and the results could be used to 
define ion-channel composition in individual neurons21-23. Chapter 5 offered an extension of 
these techniques by examining a new brain region, by using ProcConstPharm (Kevin Chase, 
University of Utah) for rapid and unbiased analysis of large data sets, and by exhibiting the 
first use of conantokins for examining NMDAR subtypes in live neurons.
In the future, neuronal profiling experiments similar to those presented in Chapter 5 
should be performed on other regions of the brain (e.g., cortex, thalamus, brainstem, frontal 
lobes, etc). Potentially, a map of the neuronal composition for the whole brain could be 
developed, which would have far-reaching influences in neuroscience and medicine. For 
example, mRNA expression patterns for NMDA receptor subtypes are well defined in 
various regions of the mammalian brain, but far less is known about function expression of 
the assembled receptors or about the subunit composition of functional NMDARs in
different brain regions throughout development3-5,24-27. Constellation pharmacology paired
with conantokin peptides presents the best opportunity to define NMDAR subunit 
composition in neurons from many brain regions during the course of development, which 
will ultimately provide insight into the physiological role played by NMDARs in brain 
development, normal brain function, and neurological disorders.
Potential f o r  technical improvements
The scientific impact of constellation pharmacology could be broadened with 
technical improvements. For example, it would be ideal to connect phenotypes observed for 
dissociated cells to neurons found in intact brains. In parallel with this goal, two techniques 
are currently being pursued that exploit cell-specific gene expression: 1) The use of
immunohistochemistry to label neurons expressing a specific protein and 2) the use of 
genetic mouse models with cell-specific expression of fluorescent proteins. Successful 
integration of these methods will strengthen conclusions drawn from constellation 
pharmacology and allow hypothesis to be tested using less intrusive methods.
In addition to imaging individual dissociated neurons, imaging connected networks 
of neurons slice (while retaining single cell resolution) would be beneficial. Examination of 
neural networks with constellation pharmacology would allow additional questions to be 
answered. For example, NMDA receptors have significant influence on synaptic plasticity 
and activation of NMDARs generally strengthens synaptic connections28-30. Yet, it is unclear 
whether these changes are dependent on NMDAR subtypes and it is unclear what 
mechanisms drive synaptic gain. Imaging connected networks, combined with the use of 
selective conantokin peptides, would allow examination of synaptic plasticity in real time and 
facilitate determination of NMDAR subtype dependency, if present.
There are, however, challenges associated with calcium imaging of neurons within a 
slice. Of note, high background levels present for slices loaded with fluorescent dye would 
need to be overcome. Maybe this challenge could be circumnavigated by injecting dye 
directly into cells through glass microelectrodes. Under these conditions, background 
fluorescence can be removed from closely spaced neuronal milieus and individual neurons 
can be observed in a more natural setting. Ultimately, imaging neural networks would extend 
the reach of constellation pharmacology by facilitating experiments that observe the 
emergent properties of natural neural networks.
Screening Conus venoms with calcium imaging 
Constellation pharmacology also provides a new platform for high-content screening 
of animal venoms for neuro-active compounds. As ion-channel compositions of individual
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neurons are defined, those neuronal phenotypes become readout for screening assays. 
Specifically, neurons expressing a precise ion channel subtype can be used to screen for 
compounds that influence that exact channel. Also, as more neuronal phenotypes are 
defined, screening methods will continually improve, which in turn will lead to discovery of 
additional tools that aide with defining neuronal phenotypes. This, in essence, is a positive 
feedback loop with the rate of discovering novel toxins positively linked to the rate of 
categorizing neurons. At some critical point, both processes should accelerate significantly, 
and once that point is achieved the challenge of screening thousands of agents on Conus 
venoms will cease to be daunting.
In order to illustrate the applicability of constellation pharmacology for screening, 
experiments are currently being performed to screen for conantokin peptides that inhibit 
NMDA responses from cerebellar neurons. Based on what we currently know of NMDA 
receptor composition in mouse cerebellum, at least three possibilities exist for the results of 
these screens. 1) Discovery of an NR2B-selective conantokin, 2) discovery of novel NR2C- 
selective conantokins, or 3) discovery of conantokins that may be selective for triheteromeric 
NR12-NR2B-NR2C NMDARs. The latter two possibilities present the most exciting 
potential outcomes for two reasons: no NR2C selective conantokins have been discovered 
date, and it is unknown whether conantokins can specifically target triheteromeric receptors.
Looking forward, as additional regions of the brain are characterized with 
constellation pharmacology and conantokin peptides, it is likely we will encounter cells that 
express NMDAR combinations that have not yet been appreciated. As the NMDARs in 
these cells are characterized, these cells can be used to screen for conantokins with unique 
NMDAR selectivity. Even if agents with high NMDAR selectivity are not found in Conus 
venoms, these techniques can be extended to screen any animal venom or natural product
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source (e.g., spider venoms, wasp venoms, sea anemones). Furthermore, similar approaches 
can be used to identify ligands for many of the non-NMDAR ion channels found in 
mammalian neurons. Thus, it is an exciting time for neurobiologists who incorporate 
calcium imaging and constellation pharmacology techniques.
Perspectives on the future of neuroscience 
This dissertation has presented scientific results spanning many orders of magnitude. 
From the atomic details of conantokin peptides to the use of conantokin peptides in 
understanding NMDARs of mammalian neurons, the ideas presented here begin to connect 
the molecular level with the cellular level of the nervous system. To inclusively understand 
nervous system function, future scientists will need to combine ideas taken from the many 
levels at which nervous systems can be studied. Studying atoms, proteins, protein complexes, 
organelles, cells, synapses, and neuronal networks has value, yet singular studies limit the 
ability to develop comprehensive models of nervous system function. Combining results 
from various disciplines and levels of study may one day unveil how nonsentient physical 
objects organize to create sentient networks via molecular and cellular interactions. Clearly, 
Conus venoms harbor tools that can be used to bridge many levels of nervous system 
organization, and I am optimistic that conotoxins will contribute significantly to our 
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